Systemic Racism and Health Disparities: A Statement from Editors of Family Medicine Journals

Article Type
Changed
Fri, 01/29/2021 - 14:59
Display Headline
Systemic Racism and Health Disparities: A Statement from Editors of Family Medicine Journals

The year 2020 was marked by historic protests across the United States and the globe sparked by the deaths of George Floyd, Ahmaud Arbery, Breonna Taylor, and so many other Black people. The protests heightened awareness of racism as a public health crisis and triggered an antiracism movement. Racism is a pervasive and systemic issue that has profound adverse effects on health.1,2 Racism is associated with poorer mental and physical health outcomes and negative patient experiences in the health care system.3,4 As evidenced by the current coronavirus pandemic, race is a sociopolitical construct that continues to disadvantage Black, Latinx, Indigenous, and other People of Color.5,6,7,8 The association between racism and adverse health outcomes has been discussed for decades in the medical literature, including the family medicine literature. Today there is a renewed call to action for family medicine, a specialty that emerged as a counterculture to reform mainstream medicine,9 to both confront systemic racism and eliminate health disparities. This effort will require collaboration, commitment, education, and transformative conversations around racism, health inequity, and advocacy so that we can better serve our patients and our communities.

The editors of several North American family medicine publications have come together to address this call to action and share resources on racism across our readerships. We acknowledge those members of the family medicine scholar community who have been fighting for equity consistent with the Black Lives Matter movement by writing about racism, health inequities, and personal experiences of practicing as Black family physicians. While we recognize that much more work is needed, we want to amplify these voices. We have compiled a bibliography of scholarship generated by the family medicine community on the topic of racism in medicine.

The collection can be accessed here.

While this list is likely not complete, it does include over 250 published manuscripts and demonstrates expertise as well as a commitment to addressing these complex issues. For example, in 2016, Dr. J. Nwando Olayiwola, chair of the Department of Family Medicine at Ohio State University, wrote an essay on her experiences taking care of patients as a Black family physician.10 In January of 2019, Family Medicine published an entire issue devoted to racism in education and training.11 Dr. Eduardo Medina, a family physician and public health scholar, co-authored a call to action in 2016 for health professionals to dismantle structural racism and support Black lives to achieve health equity. His recent 2020 article builds on that theme and describes the disproportionate deaths of Black people due to racial injustice and the COVID-19 pandemic as converging public health emergencies.12,13 In the wake of these emergencies a fundamental transformation is warranted, and family physicians can play a key role.

We, the editors of family medicine journals, commit to actively examine the effects of racism on society and health and to take action to eliminate structural racism in our editorial processes. As an intellectual home for our profession, we have a unique responsibility and opportunity to educate and continue the conversation about institutional racism, health inequities, and antiracism in medicine. We will take immediate steps to enact tangible advances on these fronts. We will encourage and mentor authors from groups underrepresented in medicine. We will ensure that content includes an emphasis on cultural humility, diversity and inclusion, implicit bias, and the impact of racism on medicine and health. We will recruit editors and editorial board members from groups underrepresented in medicine. We will encourage collaboration and accountability within our specialty to confront systemic racism through content and processes in all of our individual publications. We recognize that these are small steps in an ongoing process of active antiracism, but we believe these steps are crucial. As editors in family medicine, we are committed to progress toward equity and justice.

Simultaneously published in American Family Physician, Annals of Family Medicine, Canadian Family Physician, Family Medicine, FP Essentials, FPIN/Evidence Based Practice, FPM, Journal of the American Board of Family Medicine, The Journal of Family Practice, and PRiMER.

Acknowledgement –

The authors thank Renee Crichlow, MD, Byron Jasper, MD, MPH, and Victoria Murrain, DO, for their insightful comments on this editorial.

References

1. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, Smedley BD, Stith AY, Nelson AR, eds. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press; 2003.

2. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453-1463. 

3. Ben J, Cormack D, Harris R, Paradies Y. Racism and health service utilisation: A systematic review and meta-analysis. PLoS One. 2017;12(12):e0189900.

4. Paradies Y, Ben J, Denson N, et al. Racism as a determinant of health: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0138511.

5. American Academy of Family Physicians. Institutional racism in the health care system. Published 2019. Accessed Sept. 15, 2020. https://www.aafp.org/about/policies/all/institutional-racism.html.

6. Yaya S, Yeboah H, Charles CH, Otu A, Labonte R. Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. BMJ Glob Health. 2020;5(6):e002913. 

7. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 — A Dangerous Convergence for Black Americans [published online ahead of print, 2020 Jul 22]. N Engl J Med. 2020;10.1056/NEJMp2023616.

8. Centers for Disease Control and Prevention. Health equity considerations and racial and ethnic minority groups. Updated July 24, 2020. Accessed Sept. 15, 2020. https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html

9. Stephens GG. Family medicine as counterculture. Fam Med. 1989;21(2):103-109.

10. Olayiwola JN. Racism in medicine: shifting the power. Ann Fam Med. 2016;14(3):267-269. https://doi.org/10.1370/afm.1932.

11. Saultz J, ed. Racism. Fam Med. 2019;51(1, theme issue):1-66.

12. Hardeman RR, Medina EM, Kozhimannil KB. Structural racism and supporting black lives - the role of health professionals. N Engl J Med. 2016;375(22):2113-2115. https://doi.org/10.1056/NEJMp1609535.

13. Hardeman RR, Medina EM, Boyd RW. Stolen breaths. N Engl J Med. 2020;383(3):197-199. 10.1056/NEJMp2021072.

Article PDF
Author and Disclosure Information

Sumi M. Sexton, MD, American Family Physician; Caroline R. Richardson, MD, Annals of Family Medicine; Sarina B. Schrager, MD, MS, FPM; Marjorie A. Bowman, MD, Journal of the American Board of Family Medicine; John Hickner, MD, MSc, The Journal of Family Practice; Christopher P. Morley, PhD, MA, PRiMER; Timothy F. Mott, MD, FPIN/Evidence Based Practice; Nicholas Pimlott, MD, PhD, Canadian Family Physician; John W. Saultz, MD, Family Medicine; Barry D. Weiss, MD, FP Essentials

Issue
The Journal of Family Practice - 70(1)
Publications
Topics
Page Number
3-4. Online ahead of print, October 15, 2020
Sections
Author and Disclosure Information

Sumi M. Sexton, MD, American Family Physician; Caroline R. Richardson, MD, Annals of Family Medicine; Sarina B. Schrager, MD, MS, FPM; Marjorie A. Bowman, MD, Journal of the American Board of Family Medicine; John Hickner, MD, MSc, The Journal of Family Practice; Christopher P. Morley, PhD, MA, PRiMER; Timothy F. Mott, MD, FPIN/Evidence Based Practice; Nicholas Pimlott, MD, PhD, Canadian Family Physician; John W. Saultz, MD, Family Medicine; Barry D. Weiss, MD, FP Essentials

Author and Disclosure Information

Sumi M. Sexton, MD, American Family Physician; Caroline R. Richardson, MD, Annals of Family Medicine; Sarina B. Schrager, MD, MS, FPM; Marjorie A. Bowman, MD, Journal of the American Board of Family Medicine; John Hickner, MD, MSc, The Journal of Family Practice; Christopher P. Morley, PhD, MA, PRiMER; Timothy F. Mott, MD, FPIN/Evidence Based Practice; Nicholas Pimlott, MD, PhD, Canadian Family Physician; John W. Saultz, MD, Family Medicine; Barry D. Weiss, MD, FP Essentials

Article PDF
Article PDF

The year 2020 was marked by historic protests across the United States and the globe sparked by the deaths of George Floyd, Ahmaud Arbery, Breonna Taylor, and so many other Black people. The protests heightened awareness of racism as a public health crisis and triggered an antiracism movement. Racism is a pervasive and systemic issue that has profound adverse effects on health.1,2 Racism is associated with poorer mental and physical health outcomes and negative patient experiences in the health care system.3,4 As evidenced by the current coronavirus pandemic, race is a sociopolitical construct that continues to disadvantage Black, Latinx, Indigenous, and other People of Color.5,6,7,8 The association between racism and adverse health outcomes has been discussed for decades in the medical literature, including the family medicine literature. Today there is a renewed call to action for family medicine, a specialty that emerged as a counterculture to reform mainstream medicine,9 to both confront systemic racism and eliminate health disparities. This effort will require collaboration, commitment, education, and transformative conversations around racism, health inequity, and advocacy so that we can better serve our patients and our communities.

The editors of several North American family medicine publications have come together to address this call to action and share resources on racism across our readerships. We acknowledge those members of the family medicine scholar community who have been fighting for equity consistent with the Black Lives Matter movement by writing about racism, health inequities, and personal experiences of practicing as Black family physicians. While we recognize that much more work is needed, we want to amplify these voices. We have compiled a bibliography of scholarship generated by the family medicine community on the topic of racism in medicine.

The collection can be accessed here.

While this list is likely not complete, it does include over 250 published manuscripts and demonstrates expertise as well as a commitment to addressing these complex issues. For example, in 2016, Dr. J. Nwando Olayiwola, chair of the Department of Family Medicine at Ohio State University, wrote an essay on her experiences taking care of patients as a Black family physician.10 In January of 2019, Family Medicine published an entire issue devoted to racism in education and training.11 Dr. Eduardo Medina, a family physician and public health scholar, co-authored a call to action in 2016 for health professionals to dismantle structural racism and support Black lives to achieve health equity. His recent 2020 article builds on that theme and describes the disproportionate deaths of Black people due to racial injustice and the COVID-19 pandemic as converging public health emergencies.12,13 In the wake of these emergencies a fundamental transformation is warranted, and family physicians can play a key role.

We, the editors of family medicine journals, commit to actively examine the effects of racism on society and health and to take action to eliminate structural racism in our editorial processes. As an intellectual home for our profession, we have a unique responsibility and opportunity to educate and continue the conversation about institutional racism, health inequities, and antiracism in medicine. We will take immediate steps to enact tangible advances on these fronts. We will encourage and mentor authors from groups underrepresented in medicine. We will ensure that content includes an emphasis on cultural humility, diversity and inclusion, implicit bias, and the impact of racism on medicine and health. We will recruit editors and editorial board members from groups underrepresented in medicine. We will encourage collaboration and accountability within our specialty to confront systemic racism through content and processes in all of our individual publications. We recognize that these are small steps in an ongoing process of active antiracism, but we believe these steps are crucial. As editors in family medicine, we are committed to progress toward equity and justice.

Simultaneously published in American Family Physician, Annals of Family Medicine, Canadian Family Physician, Family Medicine, FP Essentials, FPIN/Evidence Based Practice, FPM, Journal of the American Board of Family Medicine, The Journal of Family Practice, and PRiMER.

Acknowledgement –

The authors thank Renee Crichlow, MD, Byron Jasper, MD, MPH, and Victoria Murrain, DO, for their insightful comments on this editorial.

The year 2020 was marked by historic protests across the United States and the globe sparked by the deaths of George Floyd, Ahmaud Arbery, Breonna Taylor, and so many other Black people. The protests heightened awareness of racism as a public health crisis and triggered an antiracism movement. Racism is a pervasive and systemic issue that has profound adverse effects on health.1,2 Racism is associated with poorer mental and physical health outcomes and negative patient experiences in the health care system.3,4 As evidenced by the current coronavirus pandemic, race is a sociopolitical construct that continues to disadvantage Black, Latinx, Indigenous, and other People of Color.5,6,7,8 The association between racism and adverse health outcomes has been discussed for decades in the medical literature, including the family medicine literature. Today there is a renewed call to action for family medicine, a specialty that emerged as a counterculture to reform mainstream medicine,9 to both confront systemic racism and eliminate health disparities. This effort will require collaboration, commitment, education, and transformative conversations around racism, health inequity, and advocacy so that we can better serve our patients and our communities.

The editors of several North American family medicine publications have come together to address this call to action and share resources on racism across our readerships. We acknowledge those members of the family medicine scholar community who have been fighting for equity consistent with the Black Lives Matter movement by writing about racism, health inequities, and personal experiences of practicing as Black family physicians. While we recognize that much more work is needed, we want to amplify these voices. We have compiled a bibliography of scholarship generated by the family medicine community on the topic of racism in medicine.

The collection can be accessed here.

While this list is likely not complete, it does include over 250 published manuscripts and demonstrates expertise as well as a commitment to addressing these complex issues. For example, in 2016, Dr. J. Nwando Olayiwola, chair of the Department of Family Medicine at Ohio State University, wrote an essay on her experiences taking care of patients as a Black family physician.10 In January of 2019, Family Medicine published an entire issue devoted to racism in education and training.11 Dr. Eduardo Medina, a family physician and public health scholar, co-authored a call to action in 2016 for health professionals to dismantle structural racism and support Black lives to achieve health equity. His recent 2020 article builds on that theme and describes the disproportionate deaths of Black people due to racial injustice and the COVID-19 pandemic as converging public health emergencies.12,13 In the wake of these emergencies a fundamental transformation is warranted, and family physicians can play a key role.

We, the editors of family medicine journals, commit to actively examine the effects of racism on society and health and to take action to eliminate structural racism in our editorial processes. As an intellectual home for our profession, we have a unique responsibility and opportunity to educate and continue the conversation about institutional racism, health inequities, and antiracism in medicine. We will take immediate steps to enact tangible advances on these fronts. We will encourage and mentor authors from groups underrepresented in medicine. We will ensure that content includes an emphasis on cultural humility, diversity and inclusion, implicit bias, and the impact of racism on medicine and health. We will recruit editors and editorial board members from groups underrepresented in medicine. We will encourage collaboration and accountability within our specialty to confront systemic racism through content and processes in all of our individual publications. We recognize that these are small steps in an ongoing process of active antiracism, but we believe these steps are crucial. As editors in family medicine, we are committed to progress toward equity and justice.

Simultaneously published in American Family Physician, Annals of Family Medicine, Canadian Family Physician, Family Medicine, FP Essentials, FPIN/Evidence Based Practice, FPM, Journal of the American Board of Family Medicine, The Journal of Family Practice, and PRiMER.

Acknowledgement –

The authors thank Renee Crichlow, MD, Byron Jasper, MD, MPH, and Victoria Murrain, DO, for their insightful comments on this editorial.

References

1. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, Smedley BD, Stith AY, Nelson AR, eds. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press; 2003.

2. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453-1463. 

3. Ben J, Cormack D, Harris R, Paradies Y. Racism and health service utilisation: A systematic review and meta-analysis. PLoS One. 2017;12(12):e0189900.

4. Paradies Y, Ben J, Denson N, et al. Racism as a determinant of health: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0138511.

5. American Academy of Family Physicians. Institutional racism in the health care system. Published 2019. Accessed Sept. 15, 2020. https://www.aafp.org/about/policies/all/institutional-racism.html.

6. Yaya S, Yeboah H, Charles CH, Otu A, Labonte R. Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. BMJ Glob Health. 2020;5(6):e002913. 

7. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 — A Dangerous Convergence for Black Americans [published online ahead of print, 2020 Jul 22]. N Engl J Med. 2020;10.1056/NEJMp2023616.

8. Centers for Disease Control and Prevention. Health equity considerations and racial and ethnic minority groups. Updated July 24, 2020. Accessed Sept. 15, 2020. https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html

9. Stephens GG. Family medicine as counterculture. Fam Med. 1989;21(2):103-109.

10. Olayiwola JN. Racism in medicine: shifting the power. Ann Fam Med. 2016;14(3):267-269. https://doi.org/10.1370/afm.1932.

11. Saultz J, ed. Racism. Fam Med. 2019;51(1, theme issue):1-66.

12. Hardeman RR, Medina EM, Kozhimannil KB. Structural racism and supporting black lives - the role of health professionals. N Engl J Med. 2016;375(22):2113-2115. https://doi.org/10.1056/NEJMp1609535.

13. Hardeman RR, Medina EM, Boyd RW. Stolen breaths. N Engl J Med. 2020;383(3):197-199. 10.1056/NEJMp2021072.

References

1. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, Smedley BD, Stith AY, Nelson AR, eds. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press; 2003.

2. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453-1463. 

3. Ben J, Cormack D, Harris R, Paradies Y. Racism and health service utilisation: A systematic review and meta-analysis. PLoS One. 2017;12(12):e0189900.

4. Paradies Y, Ben J, Denson N, et al. Racism as a determinant of health: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0138511.

5. American Academy of Family Physicians. Institutional racism in the health care system. Published 2019. Accessed Sept. 15, 2020. https://www.aafp.org/about/policies/all/institutional-racism.html.

6. Yaya S, Yeboah H, Charles CH, Otu A, Labonte R. Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. BMJ Glob Health. 2020;5(6):e002913. 

7. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 — A Dangerous Convergence for Black Americans [published online ahead of print, 2020 Jul 22]. N Engl J Med. 2020;10.1056/NEJMp2023616.

8. Centers for Disease Control and Prevention. Health equity considerations and racial and ethnic minority groups. Updated July 24, 2020. Accessed Sept. 15, 2020. https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html

9. Stephens GG. Family medicine as counterculture. Fam Med. 1989;21(2):103-109.

10. Olayiwola JN. Racism in medicine: shifting the power. Ann Fam Med. 2016;14(3):267-269. https://doi.org/10.1370/afm.1932.

11. Saultz J, ed. Racism. Fam Med. 2019;51(1, theme issue):1-66.

12. Hardeman RR, Medina EM, Kozhimannil KB. Structural racism and supporting black lives - the role of health professionals. N Engl J Med. 2016;375(22):2113-2115. https://doi.org/10.1056/NEJMp1609535.

13. Hardeman RR, Medina EM, Boyd RW. Stolen breaths. N Engl J Med. 2020;383(3):197-199. 10.1056/NEJMp2021072.

Issue
The Journal of Family Practice - 70(1)
Issue
The Journal of Family Practice - 70(1)
Page Number
3-4. Online ahead of print, October 15, 2020
Page Number
3-4. Online ahead of print, October 15, 2020
Publications
Publications
Topics
Article Type
Display Headline
Systemic Racism and Health Disparities: A Statement from Editors of Family Medicine Journals
Display Headline
Systemic Racism and Health Disparities: A Statement from Editors of Family Medicine Journals
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 10/09/2020 - 15:15
Un-Gate On Date
Fri, 10/09/2020 - 15:15
Use ProPublica
CFC Schedule Remove Status
Fri, 10/09/2020 - 15:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media

Human Papillomavirus Vaccination in LGBTQ Patients: The Need for Dermatologists on the Front Lines

Article Type
Changed
Thu, 10/29/2020 - 15:11

 

Human papillomavirus (HPV) is one of the most common sexually transmitted infections in the United States. It is the causative agent of genital warts, as well as cervical, anal, penile, vulvar, vaginal, and some head and neck cancers.1 Development of the HPV vaccine and its introduction into the scheduled vaccine series recommended by the Centers for Disease Control and Prevention (CDC) represented a major public health milestone. The CDC recommends the HPV vaccine for all children beginning at 11 or 12 years of age, even as early as 9 years, regardless of gender identity or sexuality. As of late 2016, the 9-valent formulation (Gardasil 9 [Merck]) is the only HPV vaccine distributed in the United States, and the vaccination schedule depends specifically on age. The Advisory Committee on Immunization Practices (ACIP) of the CDC revised its recommendations in 2019 to include “shared clinical decision-making regarding HPV vaccination . . . for some adults aged 27 through 45 years.”2 This change in policy has notable implications for sexual and gender minority populations, such as lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ) patients, especially in the context of dermatologic care. Herein, we discuss HPV-related conditions for LGBTQ patients, barriers to vaccine administration, and the role of dermatologists in promoting an increased vaccination rate in the LGBTQ community.

HPV-Related Conditions

A 2019 review of dermatologic care for LGBTQ patients identified many specific health disparities of HPV.3 Specifically, men who have sex with men (MSM) are more likely than heterosexual men to have oral, anal, and penile HPV infections, including high-risk HPV types.3 From 2011 to 2014, 18% and 13% of MSM had oral HPV infection and high-risk oral HPV infection, respectively, compared to only 11% and 7%, respectively, of men who reported never having had a same-sex sexual partner.4

Similarly, despite the CDC’s position that patients with perianal warts might benefit from digital anal examination or referral for standard or high-resolution anoscopy to detect intra-anal warts, improvements in morbidity have not yet been realized. In 2017, anal cancer incidence was 45.9 cases for every 100,000 person-years among human immunodeficiency (HIV)–positive MSM and 5.1 cases for every 100,000 person-years among HIV-negative MSM vs only 1.5 cases for every 100,000 person-years among men in the United States overall.3 Yet the CDC states that there is insufficient evidence to recommend routine anal cancer screening among MSM, even when a patient is HIV positive. Therefore, current screening practices and treatments are insufficient as MSM continue to have a disproportionately higher rate of HPV-associated disease compared to other populations.

Barriers to HPV Vaccine Administration

The HPV vaccination rate among MSM in adolescent populations varies across reports.5-7 Interestingly, a 2016 survey study found that MSM had approximately 2-times greater odds of initiating the HPV vaccine than heterosexual men.8 However, a study specifically sampling young gay and bisexual men (N=428) found that only 13% had received any doses of the HPV vaccine.6

Regardless, HPV vaccination is much less common among all males than it is among all females, and the low rate of vaccination among sexual minority men has a disproportionate impact, given their higher risk for HPV infection.4 Although the HPV vaccination rate increased from 2014 to 2017, the HPV vaccination rate in MSM overall is less than half of the Healthy People 2020 goal of 80%.9 A 2018 review determined that HPV vaccination is a cost-effective strategy for preventing anal cancer in MSM10; yet male patients might still view the HPV vaccine as a “women’s issue” and are less likely to be vaccinated if they are not prompted by health care providers. Additionally, HPV vaccination is remarkably less likely in MSM when patients are older, uninsured, of lower socioeconomic status, or have not disclosed their sexual identity to their health care provider.9 Dermatologists should be mindful of these barriers to promote HPV vaccination in MSM before, or soon after, sexual debut.



Other members of the LGBTQ community, such as women who have sex with women, face notable HPV-related health disparities and would benefit from increased vaccination efforts by dermatologists. Adolescent and young adult women who have sex with women are less likely than heterosexual adolescent and young adult women to receive routine Papanicolaou tests and initiate HPV vaccination, despite having a higher number of lifetime sexual partners and a higher risk for HPV exposure.11 A 2015 survey study (N=3253) found that after adjusting for covariates, only 8.5% of lesbians and 33.2% of bisexual women and girls who had heard of the HPV vaccine had initiated vaccination compared to 28.4% of their heterosexual counterparts.11 The HPV vaccine is an effective public health tool for the prevention of cervical cancer in these populations. A study of women aged 15 to 19 years in the HPV vaccination era (2007-2014) found significant (P<.05) observed population-level decreases in cervical intraepithelial neoplasia incidence across all grades.12

Transgender women also face a high rate of HPV infection, HIV infection, and other structural and financial disparities, such as low insurance coverage, that can limit their access to vaccination. Transgender men have a higher rate of HPV infection than cisgender men, and those with female internal reproductive organs are less likely to receive routine Papanicolaou tests. A 2018 survey study found that approximately one-third of transgender men and women reported initiating the HPV vaccination series,13 but further investigation is required to make balanced comparisons to cisgender patients.

The Role of the Dermatologist

Collectively, these disparities emphasize the need for increased involvement by dermatologists in HPV vaccination efforts for all LGBTQ patients. Adult patients may have concerns about ties of the HPV vaccine to drug manufacturers and the general safety of vaccination. For pediatric patients, parents/guardians also may be concerned about an assumed but not evidence-based increase in sexual promiscuity following HPV vaccination.14 These topics can be challenging to discuss, but dermatologists have the duty to be proactive and initiate conversation about HPV vaccination, as opposed to waiting for patients to express interest. Dermatologists should stress the safety of the vaccine as well as its potential to protect against multiple, even life-threatening diseases. Providers also can explain that the ACIP recommends catch-up vaccination for all individuals through 26 years of age, regardless of sexual orientation or gender identity.

With the ACIP having recently expanded the appropriate age range for HPV vaccination, we encourage dermatologists to engage in education and shared decision-making to ensure that adult patients with specific risk factors receive the HPV vaccine. Because the expanded ACIP recommendations are aimed at vaccination before HPV exposure, vaccination might not be appropriate for all LGBTQ patients. However, eliciting a sexual history with routine patient intake forms or during the clinical encounter ensures equal access to the HPV vaccine.

Greater awareness of HPV-related disparities and barriers to vaccination in LGBTQ populations has the potential to notably decrease HPV-associated mortality and morbidity. Increased involvement by dermatologists contributes to the efforts of other specialties in universal HPV vaccination, regardless of sexual orientation or gender identity—ideally in younger age groups, such that patients receive the vaccine prior to coitarche.



There are many ways that dermatologists can advocate for HPV vaccination. Those in a multispecialty or academic practice can readily refer patients to an associated internist, primary care physician, or vaccination clinic in the same building or institution. Dermatologists in private practice might be able to administer the HPV vaccine themselves or can advocate for patients to receive the vaccine at a local facility of the Department of Health or at a nonprofit organization, such as a Planned Parenthood center. Although pediatricians and family physicians remain front-line providers of these services, dermatologists represent an additional member of a patient’s care team, capable of advocating for this important intervention.

References
  1. Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40:80-85.
  2. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.
  3. Yeung H, Luk KM, Chen SC, et al. Dermatologic care for lesbian, gay, bisexual, and transgender persons: epidemiology, screening, and disease prevention. J Am Acad Dermatol. 2019;80:591-602.
  4. Sonawane K, Suk R, Chiao EY, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167:714-724.
  5. Kosche C, Mansh M, Luskus M, et al. Dermatologic care of sexual and gender minority/LGBTQIA youth, part 2: recognition and management of the unique dermatologic needs of SGM adolescents. Pediatr Dermatol. 2019;35:587-593.
  6. Reiter PL, McRee A-L, Katz ML, et al. Human papillomavirus vaccination among young adult gay and bisexual men in the United States. Am J Public Health. 2015;105:96-102.
  7. Charlton BM, Reisner SL, Agénor M, et al. Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Health. 2017;4:202-209.
  8. Agénor M, Peitzmeier SM, Gordon AR, et al. Sexual orientation identity disparities in human papillomavirus vaccination initiation and completion among young adult US women and men. Cancer Causes Control. 2016;27:1187-1196.
  9. Loretan C, Chamberlain AT, Sanchez T, et al. Trends and characteristics associated with human papillomavirus vaccination uptake among men who have sex with men in the United States, 2014-2017. Sex Transm Dis. 2019;46:465-473.
  10. Setiawan D, Wondimu A, Ong K, et al. Cost effectiveness of human papillomavirus vaccination for men who have sex with men; reviewing the available evidence. Pharmacoeconomics. 2018;36:929-939.
  11. Agénor M, Peitzmeier S, Gordon AR, et al. Sexual orientation identity disparities in awareness and initiation of the human papillomavirus vaccine among U.S. women and girls: a national survey. Ann Intern Med. 2015;163:99-106.
  12. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3:833-837.
  13. McRee A-L, Gower AL, Reiter PL. Preventive healthcare services use among transgender young adults. Int J Transgend. 2018;19:417-423.
  14. Trinidad J. Policy focus: promoting human papilloma virus vaccine to prevent genital warts and cancer. Boston, MA: The Fenway Institute; 2012. https://fenwayhealth.org/documents/the-fenway-institute/policy-briefs/PolicyFocus_HPV_v4_10.09.12.pdf. Accessed September 15, 2020.
Article PDF
Author and Disclosure Information

Mr. Cartron is from the Department of Dermatology, University of Maryland School of Medicine, Baltimore. Dr. Trinidad is from the Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus.

The authors report no conflict of interest.

Correspondence: Alexander M. Cartron, BS, Department of Dermatology, University of Maryland School of Medicine, 419 W Redwood St, Ste 235, Baltimore, MD 21201 ([email protected]).

Issue
Cutis - 106(4)
Publications
Topics
Page Number
159-161
Sections
Author and Disclosure Information

Mr. Cartron is from the Department of Dermatology, University of Maryland School of Medicine, Baltimore. Dr. Trinidad is from the Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus.

The authors report no conflict of interest.

Correspondence: Alexander M. Cartron, BS, Department of Dermatology, University of Maryland School of Medicine, 419 W Redwood St, Ste 235, Baltimore, MD 21201 ([email protected]).

Author and Disclosure Information

Mr. Cartron is from the Department of Dermatology, University of Maryland School of Medicine, Baltimore. Dr. Trinidad is from the Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus.

The authors report no conflict of interest.

Correspondence: Alexander M. Cartron, BS, Department of Dermatology, University of Maryland School of Medicine, 419 W Redwood St, Ste 235, Baltimore, MD 21201 ([email protected]).

Article PDF
Article PDF

 

Human papillomavirus (HPV) is one of the most common sexually transmitted infections in the United States. It is the causative agent of genital warts, as well as cervical, anal, penile, vulvar, vaginal, and some head and neck cancers.1 Development of the HPV vaccine and its introduction into the scheduled vaccine series recommended by the Centers for Disease Control and Prevention (CDC) represented a major public health milestone. The CDC recommends the HPV vaccine for all children beginning at 11 or 12 years of age, even as early as 9 years, regardless of gender identity or sexuality. As of late 2016, the 9-valent formulation (Gardasil 9 [Merck]) is the only HPV vaccine distributed in the United States, and the vaccination schedule depends specifically on age. The Advisory Committee on Immunization Practices (ACIP) of the CDC revised its recommendations in 2019 to include “shared clinical decision-making regarding HPV vaccination . . . for some adults aged 27 through 45 years.”2 This change in policy has notable implications for sexual and gender minority populations, such as lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ) patients, especially in the context of dermatologic care. Herein, we discuss HPV-related conditions for LGBTQ patients, barriers to vaccine administration, and the role of dermatologists in promoting an increased vaccination rate in the LGBTQ community.

HPV-Related Conditions

A 2019 review of dermatologic care for LGBTQ patients identified many specific health disparities of HPV.3 Specifically, men who have sex with men (MSM) are more likely than heterosexual men to have oral, anal, and penile HPV infections, including high-risk HPV types.3 From 2011 to 2014, 18% and 13% of MSM had oral HPV infection and high-risk oral HPV infection, respectively, compared to only 11% and 7%, respectively, of men who reported never having had a same-sex sexual partner.4

Similarly, despite the CDC’s position that patients with perianal warts might benefit from digital anal examination or referral for standard or high-resolution anoscopy to detect intra-anal warts, improvements in morbidity have not yet been realized. In 2017, anal cancer incidence was 45.9 cases for every 100,000 person-years among human immunodeficiency (HIV)–positive MSM and 5.1 cases for every 100,000 person-years among HIV-negative MSM vs only 1.5 cases for every 100,000 person-years among men in the United States overall.3 Yet the CDC states that there is insufficient evidence to recommend routine anal cancer screening among MSM, even when a patient is HIV positive. Therefore, current screening practices and treatments are insufficient as MSM continue to have a disproportionately higher rate of HPV-associated disease compared to other populations.

Barriers to HPV Vaccine Administration

The HPV vaccination rate among MSM in adolescent populations varies across reports.5-7 Interestingly, a 2016 survey study found that MSM had approximately 2-times greater odds of initiating the HPV vaccine than heterosexual men.8 However, a study specifically sampling young gay and bisexual men (N=428) found that only 13% had received any doses of the HPV vaccine.6

Regardless, HPV vaccination is much less common among all males than it is among all females, and the low rate of vaccination among sexual minority men has a disproportionate impact, given their higher risk for HPV infection.4 Although the HPV vaccination rate increased from 2014 to 2017, the HPV vaccination rate in MSM overall is less than half of the Healthy People 2020 goal of 80%.9 A 2018 review determined that HPV vaccination is a cost-effective strategy for preventing anal cancer in MSM10; yet male patients might still view the HPV vaccine as a “women’s issue” and are less likely to be vaccinated if they are not prompted by health care providers. Additionally, HPV vaccination is remarkably less likely in MSM when patients are older, uninsured, of lower socioeconomic status, or have not disclosed their sexual identity to their health care provider.9 Dermatologists should be mindful of these barriers to promote HPV vaccination in MSM before, or soon after, sexual debut.



Other members of the LGBTQ community, such as women who have sex with women, face notable HPV-related health disparities and would benefit from increased vaccination efforts by dermatologists. Adolescent and young adult women who have sex with women are less likely than heterosexual adolescent and young adult women to receive routine Papanicolaou tests and initiate HPV vaccination, despite having a higher number of lifetime sexual partners and a higher risk for HPV exposure.11 A 2015 survey study (N=3253) found that after adjusting for covariates, only 8.5% of lesbians and 33.2% of bisexual women and girls who had heard of the HPV vaccine had initiated vaccination compared to 28.4% of their heterosexual counterparts.11 The HPV vaccine is an effective public health tool for the prevention of cervical cancer in these populations. A study of women aged 15 to 19 years in the HPV vaccination era (2007-2014) found significant (P<.05) observed population-level decreases in cervical intraepithelial neoplasia incidence across all grades.12

Transgender women also face a high rate of HPV infection, HIV infection, and other structural and financial disparities, such as low insurance coverage, that can limit their access to vaccination. Transgender men have a higher rate of HPV infection than cisgender men, and those with female internal reproductive organs are less likely to receive routine Papanicolaou tests. A 2018 survey study found that approximately one-third of transgender men and women reported initiating the HPV vaccination series,13 but further investigation is required to make balanced comparisons to cisgender patients.

The Role of the Dermatologist

Collectively, these disparities emphasize the need for increased involvement by dermatologists in HPV vaccination efforts for all LGBTQ patients. Adult patients may have concerns about ties of the HPV vaccine to drug manufacturers and the general safety of vaccination. For pediatric patients, parents/guardians also may be concerned about an assumed but not evidence-based increase in sexual promiscuity following HPV vaccination.14 These topics can be challenging to discuss, but dermatologists have the duty to be proactive and initiate conversation about HPV vaccination, as opposed to waiting for patients to express interest. Dermatologists should stress the safety of the vaccine as well as its potential to protect against multiple, even life-threatening diseases. Providers also can explain that the ACIP recommends catch-up vaccination for all individuals through 26 years of age, regardless of sexual orientation or gender identity.

With the ACIP having recently expanded the appropriate age range for HPV vaccination, we encourage dermatologists to engage in education and shared decision-making to ensure that adult patients with specific risk factors receive the HPV vaccine. Because the expanded ACIP recommendations are aimed at vaccination before HPV exposure, vaccination might not be appropriate for all LGBTQ patients. However, eliciting a sexual history with routine patient intake forms or during the clinical encounter ensures equal access to the HPV vaccine.

Greater awareness of HPV-related disparities and barriers to vaccination in LGBTQ populations has the potential to notably decrease HPV-associated mortality and morbidity. Increased involvement by dermatologists contributes to the efforts of other specialties in universal HPV vaccination, regardless of sexual orientation or gender identity—ideally in younger age groups, such that patients receive the vaccine prior to coitarche.



There are many ways that dermatologists can advocate for HPV vaccination. Those in a multispecialty or academic practice can readily refer patients to an associated internist, primary care physician, or vaccination clinic in the same building or institution. Dermatologists in private practice might be able to administer the HPV vaccine themselves or can advocate for patients to receive the vaccine at a local facility of the Department of Health or at a nonprofit organization, such as a Planned Parenthood center. Although pediatricians and family physicians remain front-line providers of these services, dermatologists represent an additional member of a patient’s care team, capable of advocating for this important intervention.

 

Human papillomavirus (HPV) is one of the most common sexually transmitted infections in the United States. It is the causative agent of genital warts, as well as cervical, anal, penile, vulvar, vaginal, and some head and neck cancers.1 Development of the HPV vaccine and its introduction into the scheduled vaccine series recommended by the Centers for Disease Control and Prevention (CDC) represented a major public health milestone. The CDC recommends the HPV vaccine for all children beginning at 11 or 12 years of age, even as early as 9 years, regardless of gender identity or sexuality. As of late 2016, the 9-valent formulation (Gardasil 9 [Merck]) is the only HPV vaccine distributed in the United States, and the vaccination schedule depends specifically on age. The Advisory Committee on Immunization Practices (ACIP) of the CDC revised its recommendations in 2019 to include “shared clinical decision-making regarding HPV vaccination . . . for some adults aged 27 through 45 years.”2 This change in policy has notable implications for sexual and gender minority populations, such as lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ) patients, especially in the context of dermatologic care. Herein, we discuss HPV-related conditions for LGBTQ patients, barriers to vaccine administration, and the role of dermatologists in promoting an increased vaccination rate in the LGBTQ community.

HPV-Related Conditions

A 2019 review of dermatologic care for LGBTQ patients identified many specific health disparities of HPV.3 Specifically, men who have sex with men (MSM) are more likely than heterosexual men to have oral, anal, and penile HPV infections, including high-risk HPV types.3 From 2011 to 2014, 18% and 13% of MSM had oral HPV infection and high-risk oral HPV infection, respectively, compared to only 11% and 7%, respectively, of men who reported never having had a same-sex sexual partner.4

Similarly, despite the CDC’s position that patients with perianal warts might benefit from digital anal examination or referral for standard or high-resolution anoscopy to detect intra-anal warts, improvements in morbidity have not yet been realized. In 2017, anal cancer incidence was 45.9 cases for every 100,000 person-years among human immunodeficiency (HIV)–positive MSM and 5.1 cases for every 100,000 person-years among HIV-negative MSM vs only 1.5 cases for every 100,000 person-years among men in the United States overall.3 Yet the CDC states that there is insufficient evidence to recommend routine anal cancer screening among MSM, even when a patient is HIV positive. Therefore, current screening practices and treatments are insufficient as MSM continue to have a disproportionately higher rate of HPV-associated disease compared to other populations.

Barriers to HPV Vaccine Administration

The HPV vaccination rate among MSM in adolescent populations varies across reports.5-7 Interestingly, a 2016 survey study found that MSM had approximately 2-times greater odds of initiating the HPV vaccine than heterosexual men.8 However, a study specifically sampling young gay and bisexual men (N=428) found that only 13% had received any doses of the HPV vaccine.6

Regardless, HPV vaccination is much less common among all males than it is among all females, and the low rate of vaccination among sexual minority men has a disproportionate impact, given their higher risk for HPV infection.4 Although the HPV vaccination rate increased from 2014 to 2017, the HPV vaccination rate in MSM overall is less than half of the Healthy People 2020 goal of 80%.9 A 2018 review determined that HPV vaccination is a cost-effective strategy for preventing anal cancer in MSM10; yet male patients might still view the HPV vaccine as a “women’s issue” and are less likely to be vaccinated if they are not prompted by health care providers. Additionally, HPV vaccination is remarkably less likely in MSM when patients are older, uninsured, of lower socioeconomic status, or have not disclosed their sexual identity to their health care provider.9 Dermatologists should be mindful of these barriers to promote HPV vaccination in MSM before, or soon after, sexual debut.



Other members of the LGBTQ community, such as women who have sex with women, face notable HPV-related health disparities and would benefit from increased vaccination efforts by dermatologists. Adolescent and young adult women who have sex with women are less likely than heterosexual adolescent and young adult women to receive routine Papanicolaou tests and initiate HPV vaccination, despite having a higher number of lifetime sexual partners and a higher risk for HPV exposure.11 A 2015 survey study (N=3253) found that after adjusting for covariates, only 8.5% of lesbians and 33.2% of bisexual women and girls who had heard of the HPV vaccine had initiated vaccination compared to 28.4% of their heterosexual counterparts.11 The HPV vaccine is an effective public health tool for the prevention of cervical cancer in these populations. A study of women aged 15 to 19 years in the HPV vaccination era (2007-2014) found significant (P<.05) observed population-level decreases in cervical intraepithelial neoplasia incidence across all grades.12

Transgender women also face a high rate of HPV infection, HIV infection, and other structural and financial disparities, such as low insurance coverage, that can limit their access to vaccination. Transgender men have a higher rate of HPV infection than cisgender men, and those with female internal reproductive organs are less likely to receive routine Papanicolaou tests. A 2018 survey study found that approximately one-third of transgender men and women reported initiating the HPV vaccination series,13 but further investigation is required to make balanced comparisons to cisgender patients.

The Role of the Dermatologist

Collectively, these disparities emphasize the need for increased involvement by dermatologists in HPV vaccination efforts for all LGBTQ patients. Adult patients may have concerns about ties of the HPV vaccine to drug manufacturers and the general safety of vaccination. For pediatric patients, parents/guardians also may be concerned about an assumed but not evidence-based increase in sexual promiscuity following HPV vaccination.14 These topics can be challenging to discuss, but dermatologists have the duty to be proactive and initiate conversation about HPV vaccination, as opposed to waiting for patients to express interest. Dermatologists should stress the safety of the vaccine as well as its potential to protect against multiple, even life-threatening diseases. Providers also can explain that the ACIP recommends catch-up vaccination for all individuals through 26 years of age, regardless of sexual orientation or gender identity.

With the ACIP having recently expanded the appropriate age range for HPV vaccination, we encourage dermatologists to engage in education and shared decision-making to ensure that adult patients with specific risk factors receive the HPV vaccine. Because the expanded ACIP recommendations are aimed at vaccination before HPV exposure, vaccination might not be appropriate for all LGBTQ patients. However, eliciting a sexual history with routine patient intake forms or during the clinical encounter ensures equal access to the HPV vaccine.

Greater awareness of HPV-related disparities and barriers to vaccination in LGBTQ populations has the potential to notably decrease HPV-associated mortality and morbidity. Increased involvement by dermatologists contributes to the efforts of other specialties in universal HPV vaccination, regardless of sexual orientation or gender identity—ideally in younger age groups, such that patients receive the vaccine prior to coitarche.



There are many ways that dermatologists can advocate for HPV vaccination. Those in a multispecialty or academic practice can readily refer patients to an associated internist, primary care physician, or vaccination clinic in the same building or institution. Dermatologists in private practice might be able to administer the HPV vaccine themselves or can advocate for patients to receive the vaccine at a local facility of the Department of Health or at a nonprofit organization, such as a Planned Parenthood center. Although pediatricians and family physicians remain front-line providers of these services, dermatologists represent an additional member of a patient’s care team, capable of advocating for this important intervention.

References
  1. Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40:80-85.
  2. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.
  3. Yeung H, Luk KM, Chen SC, et al. Dermatologic care for lesbian, gay, bisexual, and transgender persons: epidemiology, screening, and disease prevention. J Am Acad Dermatol. 2019;80:591-602.
  4. Sonawane K, Suk R, Chiao EY, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167:714-724.
  5. Kosche C, Mansh M, Luskus M, et al. Dermatologic care of sexual and gender minority/LGBTQIA youth, part 2: recognition and management of the unique dermatologic needs of SGM adolescents. Pediatr Dermatol. 2019;35:587-593.
  6. Reiter PL, McRee A-L, Katz ML, et al. Human papillomavirus vaccination among young adult gay and bisexual men in the United States. Am J Public Health. 2015;105:96-102.
  7. Charlton BM, Reisner SL, Agénor M, et al. Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Health. 2017;4:202-209.
  8. Agénor M, Peitzmeier SM, Gordon AR, et al. Sexual orientation identity disparities in human papillomavirus vaccination initiation and completion among young adult US women and men. Cancer Causes Control. 2016;27:1187-1196.
  9. Loretan C, Chamberlain AT, Sanchez T, et al. Trends and characteristics associated with human papillomavirus vaccination uptake among men who have sex with men in the United States, 2014-2017. Sex Transm Dis. 2019;46:465-473.
  10. Setiawan D, Wondimu A, Ong K, et al. Cost effectiveness of human papillomavirus vaccination for men who have sex with men; reviewing the available evidence. Pharmacoeconomics. 2018;36:929-939.
  11. Agénor M, Peitzmeier S, Gordon AR, et al. Sexual orientation identity disparities in awareness and initiation of the human papillomavirus vaccine among U.S. women and girls: a national survey. Ann Intern Med. 2015;163:99-106.
  12. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3:833-837.
  13. McRee A-L, Gower AL, Reiter PL. Preventive healthcare services use among transgender young adults. Int J Transgend. 2018;19:417-423.
  14. Trinidad J. Policy focus: promoting human papilloma virus vaccine to prevent genital warts and cancer. Boston, MA: The Fenway Institute; 2012. https://fenwayhealth.org/documents/the-fenway-institute/policy-briefs/PolicyFocus_HPV_v4_10.09.12.pdf. Accessed September 15, 2020.
References
  1. Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40:80-85.
  2. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.
  3. Yeung H, Luk KM, Chen SC, et al. Dermatologic care for lesbian, gay, bisexual, and transgender persons: epidemiology, screening, and disease prevention. J Am Acad Dermatol. 2019;80:591-602.
  4. Sonawane K, Suk R, Chiao EY, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167:714-724.
  5. Kosche C, Mansh M, Luskus M, et al. Dermatologic care of sexual and gender minority/LGBTQIA youth, part 2: recognition and management of the unique dermatologic needs of SGM adolescents. Pediatr Dermatol. 2019;35:587-593.
  6. Reiter PL, McRee A-L, Katz ML, et al. Human papillomavirus vaccination among young adult gay and bisexual men in the United States. Am J Public Health. 2015;105:96-102.
  7. Charlton BM, Reisner SL, Agénor M, et al. Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Health. 2017;4:202-209.
  8. Agénor M, Peitzmeier SM, Gordon AR, et al. Sexual orientation identity disparities in human papillomavirus vaccination initiation and completion among young adult US women and men. Cancer Causes Control. 2016;27:1187-1196.
  9. Loretan C, Chamberlain AT, Sanchez T, et al. Trends and characteristics associated with human papillomavirus vaccination uptake among men who have sex with men in the United States, 2014-2017. Sex Transm Dis. 2019;46:465-473.
  10. Setiawan D, Wondimu A, Ong K, et al. Cost effectiveness of human papillomavirus vaccination for men who have sex with men; reviewing the available evidence. Pharmacoeconomics. 2018;36:929-939.
  11. Agénor M, Peitzmeier S, Gordon AR, et al. Sexual orientation identity disparities in awareness and initiation of the human papillomavirus vaccine among U.S. women and girls: a national survey. Ann Intern Med. 2015;163:99-106.
  12. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3:833-837.
  13. McRee A-L, Gower AL, Reiter PL. Preventive healthcare services use among transgender young adults. Int J Transgend. 2018;19:417-423.
  14. Trinidad J. Policy focus: promoting human papilloma virus vaccine to prevent genital warts and cancer. Boston, MA: The Fenway Institute; 2012. https://fenwayhealth.org/documents/the-fenway-institute/policy-briefs/PolicyFocus_HPV_v4_10.09.12.pdf. Accessed September 15, 2020.
Issue
Cutis - 106(4)
Issue
Cutis - 106(4)
Page Number
159-161
Page Number
159-161
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media

HM20 Virtual: Combating racism in medicine

Article Type
Changed
Thu, 08/26/2021 - 15:59

 

HM20 Virtual session title

When Grief and Crises Intersect: Perspectives of a Black Physician in the Time of Two Pandemics
 

Presenter

Kimberly Manning, MD, FACP, FAAP
 

Session summary

Dr. Vignesh Doraiswamy, assistant professor of medicine and pediatrics and a med-peds hospitalist at The Ohio State University and Nationwide Children's Hospital, Columbus
Dr. Vignesh Doraiswamy

Dr. Kimberly Manning, associate vice chair of diversity, equity, and inclusion at Emory University, Atlanta, masterfully discussed the dual pandemics of COVID-19 and racism that we are currently experiencing and tried to describe the unique perspective of Black Americans.

Though it is easy to see that COVID-19 is a pandemic, racism is not always seen in this way. Dr. Manning demonstrated that when a pandemic is defined as “that which occurs over a wide geographic area and affects a high proportion of the population,” racism is absolutely a pandemic. She gave a great analogy: when sticking your hand into a bowl of Lucky Charms cereal, you do not expect to always end up with marshmallows alone, yet repeatedly, we see that Black Americans have been disproportionately affected by COVID-19. We often hear that we are in unprecedented times but as far as racism is concerned, there is nothing new about this.

Dr. Manning discussed the life stories of her grandfather, her father, and even her own life’s milestones such as starting college, getting into medical school, finishing residency – all the way to becoming a full professor. She described how each of these instances, though marked by something beautiful, was also marked by something truly awful. Each time she had a reason to smile and laugh, there was something awful happening in the country simultaneously that showed us how racism was still present. Though this was one person’s story, all Black Americans, not just those working in health care, can recount similar stories, emotions, and feelings of grief.

Dr. Manning concluded by telling us how we can “Do the Work” to combat the pandemic of racism:

  • Broaden your fund of knowledge: Read books, listen to podcasts, watch documentaries.
  • Remember that people are grieving.
  • Explore your implicit biases.
  • Be a brave bystander.
  • Avoid performative allyship.

Key takeaways

  • Though the COVID-19 pandemic is unprecedented, the pandemic of racism is not.
  • The story of COVID-19 is the story of social determinants of health.
  • We all must “Do the Work” to combat everyday racism and be cognizant of what our Black colleagues are going through every day.

Dr. Doraiswamy is an assistant professor of medicine and pediatrics and a med-peds hospitalist at The Ohio State University and Nationwide Children’s Hospital, Columbus.

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

HM20 Virtual session title

When Grief and Crises Intersect: Perspectives of a Black Physician in the Time of Two Pandemics
 

Presenter

Kimberly Manning, MD, FACP, FAAP
 

Session summary

Dr. Vignesh Doraiswamy, assistant professor of medicine and pediatrics and a med-peds hospitalist at The Ohio State University and Nationwide Children's Hospital, Columbus
Dr. Vignesh Doraiswamy

Dr. Kimberly Manning, associate vice chair of diversity, equity, and inclusion at Emory University, Atlanta, masterfully discussed the dual pandemics of COVID-19 and racism that we are currently experiencing and tried to describe the unique perspective of Black Americans.

Though it is easy to see that COVID-19 is a pandemic, racism is not always seen in this way. Dr. Manning demonstrated that when a pandemic is defined as “that which occurs over a wide geographic area and affects a high proportion of the population,” racism is absolutely a pandemic. She gave a great analogy: when sticking your hand into a bowl of Lucky Charms cereal, you do not expect to always end up with marshmallows alone, yet repeatedly, we see that Black Americans have been disproportionately affected by COVID-19. We often hear that we are in unprecedented times but as far as racism is concerned, there is nothing new about this.

Dr. Manning discussed the life stories of her grandfather, her father, and even her own life’s milestones such as starting college, getting into medical school, finishing residency – all the way to becoming a full professor. She described how each of these instances, though marked by something beautiful, was also marked by something truly awful. Each time she had a reason to smile and laugh, there was something awful happening in the country simultaneously that showed us how racism was still present. Though this was one person’s story, all Black Americans, not just those working in health care, can recount similar stories, emotions, and feelings of grief.

Dr. Manning concluded by telling us how we can “Do the Work” to combat the pandemic of racism:

  • Broaden your fund of knowledge: Read books, listen to podcasts, watch documentaries.
  • Remember that people are grieving.
  • Explore your implicit biases.
  • Be a brave bystander.
  • Avoid performative allyship.

Key takeaways

  • Though the COVID-19 pandemic is unprecedented, the pandemic of racism is not.
  • The story of COVID-19 is the story of social determinants of health.
  • We all must “Do the Work” to combat everyday racism and be cognizant of what our Black colleagues are going through every day.

Dr. Doraiswamy is an assistant professor of medicine and pediatrics and a med-peds hospitalist at The Ohio State University and Nationwide Children’s Hospital, Columbus.

 

HM20 Virtual session title

When Grief and Crises Intersect: Perspectives of a Black Physician in the Time of Two Pandemics
 

Presenter

Kimberly Manning, MD, FACP, FAAP
 

Session summary

Dr. Vignesh Doraiswamy, assistant professor of medicine and pediatrics and a med-peds hospitalist at The Ohio State University and Nationwide Children's Hospital, Columbus
Dr. Vignesh Doraiswamy

Dr. Kimberly Manning, associate vice chair of diversity, equity, and inclusion at Emory University, Atlanta, masterfully discussed the dual pandemics of COVID-19 and racism that we are currently experiencing and tried to describe the unique perspective of Black Americans.

Though it is easy to see that COVID-19 is a pandemic, racism is not always seen in this way. Dr. Manning demonstrated that when a pandemic is defined as “that which occurs over a wide geographic area and affects a high proportion of the population,” racism is absolutely a pandemic. She gave a great analogy: when sticking your hand into a bowl of Lucky Charms cereal, you do not expect to always end up with marshmallows alone, yet repeatedly, we see that Black Americans have been disproportionately affected by COVID-19. We often hear that we are in unprecedented times but as far as racism is concerned, there is nothing new about this.

Dr. Manning discussed the life stories of her grandfather, her father, and even her own life’s milestones such as starting college, getting into medical school, finishing residency – all the way to becoming a full professor. She described how each of these instances, though marked by something beautiful, was also marked by something truly awful. Each time she had a reason to smile and laugh, there was something awful happening in the country simultaneously that showed us how racism was still present. Though this was one person’s story, all Black Americans, not just those working in health care, can recount similar stories, emotions, and feelings of grief.

Dr. Manning concluded by telling us how we can “Do the Work” to combat the pandemic of racism:

  • Broaden your fund of knowledge: Read books, listen to podcasts, watch documentaries.
  • Remember that people are grieving.
  • Explore your implicit biases.
  • Be a brave bystander.
  • Avoid performative allyship.

Key takeaways

  • Though the COVID-19 pandemic is unprecedented, the pandemic of racism is not.
  • The story of COVID-19 is the story of social determinants of health.
  • We all must “Do the Work” to combat everyday racism and be cognizant of what our Black colleagues are going through every day.

Dr. Doraiswamy is an assistant professor of medicine and pediatrics and a med-peds hospitalist at The Ohio State University and Nationwide Children’s Hospital, Columbus.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article

Defining excellence with Dr. Kimberly Manning

Article Type
Changed
Thu, 10/29/2020 - 14:05

2020 SHM Award of Excellence winner: Diversity Leadership

Each year, the Society of Hospital Medicine celebrates the exemplary actions and successes of its members through the Awards of Excellence program. Nominations open every fall, providing the SHM community with the opportunity to nominate a peer, or themselves, to receive an esteemed award of excellence in an array of categories including Teaching, Outstanding Service in Hospital Medicine, Research, and so many others.

While the program and its Awards Committee review nominations with a predetermined set of criteria, excellence is not a ‘one-size-fits-all’ defined term.

Dr. Kimberly Manning


Kimberly D. Manning, MD, FACP, FAAP, is a professor of medicine and associate vice chair of Diversity, Equity and Inclusion at the Emory University School of Medicine and a hospitalist at Grady Memorial Hospital, both in Atlanta. She believes that every single person contributes something uniquely meaningful, and that it is up to each person to decide how to use their influence to make an impact.

“To me, being excellent is about discovering your mission and pushing yourself to explore ways to be the best steward of that mission,” Dr. Manning said. “My mission is focused on serving underserved populations, humanizing patients, and amplifying voices of those who have traditionally been silenced.”

Dr. Manning has challenged herself to be the best steward of her evolving mission for equity, representation, and accessibility in medical education and health care innovation for many years. An active member of SHM for 14 years and an inspiring social impact–driven hospitalist of 20 years, Dr. Manning is known for her extensive work in the diversity, equity, and inclusion (DEI) space.

In 2020, Dr. Manning was nominated for and received SHM’s inaugural Excellence in Diversity Leadership Award by her peer and colleague, Dr. Daniel Dressler of Emory University School of Medicine.

She was honored for her commitment to improving the care of underrepresented patient populations, increasing awareness of DEI necessity, and building inclusive communities. In addition to these noteworthy achievements, she demonstrated scholarship on diversity, equity, and inclusion.

One way that Dr. Manning is fusing her love for diversity, equity, and inclusion with innovation is through her role as associate vice chair of the DEI department of Emory University’s School of Medicine. Within the department’s programs, resources and affinity groups, Dr. Manning leads a Virtual Visiting Clerkship Program for underrepresented medical students interested in pursuing a career in internal medicine.

“It includes coaching, mentorship, and diagnostic reasoning in an intimate and personal way,” she explained. “It makes me wish I were a medical student!”

In addition to her patient-centric and student-focused initiatives in Atlanta, Dr. Manning is an active contributor to SHM’s publications, including the Journal of Hospital Medicine and The Hospital Leader blog, in speaking out about racism in medicine, and other social inequities in health care. She even helped to lead a #JHMchat discussion on Twitter around these topics.

In fact, beyond being presented with the Diversity Leadership Award, she says that SHM and JHM have really demonstrated a strong commitment to diversity, equity, and inclusion.

“If you are a person with a lived experience or a person who is underrepresented in medicine, a lot of this work in diversity, equity, and inclusion never really had a name. It was called survival and looking out for each other,” Dr. Manning explained. “It’s exciting to be in this space now where there is focused, professional attention being given to something so important in our clinical and learning environments.”

SHM continues to reaffirm its longstanding commitment to diversity and inclusion and is dedicated to supporting and learning from its diverse member community. While SHM’s new Excellence in Diversity Leadership award is symbolic of a step in the right direction of change, Dr. Manning says that it is also an honor to be recognized for her areas of expertise and passion.

But that recognition moves far beyond this award. With so many more ways to connect with one another, Dr. Manning, a self-proclaimed optimist, says that one of the most exciting changes is centered on communication.

“For us to move the needle on anti-racism and representation, and to do more for our patients and colleagues, it must be a shared conversation. I feel particularly optimistic that I’m able to be more transparent than ever. I’m saying things to people whom I would have been too scared to say them to in the past.

“We’re hungry to grow and learn together,” she continued. “People are interacting in a more positive and constructive way. I’m so glad that we’re pushing diversity and you can see that a lot of people want to see us do better with this. We can continue to do better with this.”

SHM’s 2020-2021 Awards of Excellence nominations are now open with nine unique categories, including Excellence in Diversity, Equity, and Inclusion Leadership. If you have a peer or colleague in mind, like Dr. Manning, who has made exceptional contributions to DEI, or another important domain in hospital medicine, submit your nomination by Sept. 28, 2020.

“I have a feeling that this year has provided a lot of opportunity for people to emerge. The Committee is going to have a very, very tough job,” Dr. Manning said. “They are going to have some exciting nominations on their hands!”

Ms. Cowan is the marketing communications specialist at the Society of Hospital Medicine.

Publications
Topics
Sections

2020 SHM Award of Excellence winner: Diversity Leadership

2020 SHM Award of Excellence winner: Diversity Leadership

Each year, the Society of Hospital Medicine celebrates the exemplary actions and successes of its members through the Awards of Excellence program. Nominations open every fall, providing the SHM community with the opportunity to nominate a peer, or themselves, to receive an esteemed award of excellence in an array of categories including Teaching, Outstanding Service in Hospital Medicine, Research, and so many others.

While the program and its Awards Committee review nominations with a predetermined set of criteria, excellence is not a ‘one-size-fits-all’ defined term.

Dr. Kimberly Manning


Kimberly D. Manning, MD, FACP, FAAP, is a professor of medicine and associate vice chair of Diversity, Equity and Inclusion at the Emory University School of Medicine and a hospitalist at Grady Memorial Hospital, both in Atlanta. She believes that every single person contributes something uniquely meaningful, and that it is up to each person to decide how to use their influence to make an impact.

“To me, being excellent is about discovering your mission and pushing yourself to explore ways to be the best steward of that mission,” Dr. Manning said. “My mission is focused on serving underserved populations, humanizing patients, and amplifying voices of those who have traditionally been silenced.”

Dr. Manning has challenged herself to be the best steward of her evolving mission for equity, representation, and accessibility in medical education and health care innovation for many years. An active member of SHM for 14 years and an inspiring social impact–driven hospitalist of 20 years, Dr. Manning is known for her extensive work in the diversity, equity, and inclusion (DEI) space.

In 2020, Dr. Manning was nominated for and received SHM’s inaugural Excellence in Diversity Leadership Award by her peer and colleague, Dr. Daniel Dressler of Emory University School of Medicine.

She was honored for her commitment to improving the care of underrepresented patient populations, increasing awareness of DEI necessity, and building inclusive communities. In addition to these noteworthy achievements, she demonstrated scholarship on diversity, equity, and inclusion.

One way that Dr. Manning is fusing her love for diversity, equity, and inclusion with innovation is through her role as associate vice chair of the DEI department of Emory University’s School of Medicine. Within the department’s programs, resources and affinity groups, Dr. Manning leads a Virtual Visiting Clerkship Program for underrepresented medical students interested in pursuing a career in internal medicine.

“It includes coaching, mentorship, and diagnostic reasoning in an intimate and personal way,” she explained. “It makes me wish I were a medical student!”

In addition to her patient-centric and student-focused initiatives in Atlanta, Dr. Manning is an active contributor to SHM’s publications, including the Journal of Hospital Medicine and The Hospital Leader blog, in speaking out about racism in medicine, and other social inequities in health care. She even helped to lead a #JHMchat discussion on Twitter around these topics.

In fact, beyond being presented with the Diversity Leadership Award, she says that SHM and JHM have really demonstrated a strong commitment to diversity, equity, and inclusion.

“If you are a person with a lived experience or a person who is underrepresented in medicine, a lot of this work in diversity, equity, and inclusion never really had a name. It was called survival and looking out for each other,” Dr. Manning explained. “It’s exciting to be in this space now where there is focused, professional attention being given to something so important in our clinical and learning environments.”

SHM continues to reaffirm its longstanding commitment to diversity and inclusion and is dedicated to supporting and learning from its diverse member community. While SHM’s new Excellence in Diversity Leadership award is symbolic of a step in the right direction of change, Dr. Manning says that it is also an honor to be recognized for her areas of expertise and passion.

But that recognition moves far beyond this award. With so many more ways to connect with one another, Dr. Manning, a self-proclaimed optimist, says that one of the most exciting changes is centered on communication.

“For us to move the needle on anti-racism and representation, and to do more for our patients and colleagues, it must be a shared conversation. I feel particularly optimistic that I’m able to be more transparent than ever. I’m saying things to people whom I would have been too scared to say them to in the past.

“We’re hungry to grow and learn together,” she continued. “People are interacting in a more positive and constructive way. I’m so glad that we’re pushing diversity and you can see that a lot of people want to see us do better with this. We can continue to do better with this.”

SHM’s 2020-2021 Awards of Excellence nominations are now open with nine unique categories, including Excellence in Diversity, Equity, and Inclusion Leadership. If you have a peer or colleague in mind, like Dr. Manning, who has made exceptional contributions to DEI, or another important domain in hospital medicine, submit your nomination by Sept. 28, 2020.

“I have a feeling that this year has provided a lot of opportunity for people to emerge. The Committee is going to have a very, very tough job,” Dr. Manning said. “They are going to have some exciting nominations on their hands!”

Ms. Cowan is the marketing communications specialist at the Society of Hospital Medicine.

Each year, the Society of Hospital Medicine celebrates the exemplary actions and successes of its members through the Awards of Excellence program. Nominations open every fall, providing the SHM community with the opportunity to nominate a peer, or themselves, to receive an esteemed award of excellence in an array of categories including Teaching, Outstanding Service in Hospital Medicine, Research, and so many others.

While the program and its Awards Committee review nominations with a predetermined set of criteria, excellence is not a ‘one-size-fits-all’ defined term.

Dr. Kimberly Manning


Kimberly D. Manning, MD, FACP, FAAP, is a professor of medicine and associate vice chair of Diversity, Equity and Inclusion at the Emory University School of Medicine and a hospitalist at Grady Memorial Hospital, both in Atlanta. She believes that every single person contributes something uniquely meaningful, and that it is up to each person to decide how to use their influence to make an impact.

“To me, being excellent is about discovering your mission and pushing yourself to explore ways to be the best steward of that mission,” Dr. Manning said. “My mission is focused on serving underserved populations, humanizing patients, and amplifying voices of those who have traditionally been silenced.”

Dr. Manning has challenged herself to be the best steward of her evolving mission for equity, representation, and accessibility in medical education and health care innovation for many years. An active member of SHM for 14 years and an inspiring social impact–driven hospitalist of 20 years, Dr. Manning is known for her extensive work in the diversity, equity, and inclusion (DEI) space.

In 2020, Dr. Manning was nominated for and received SHM’s inaugural Excellence in Diversity Leadership Award by her peer and colleague, Dr. Daniel Dressler of Emory University School of Medicine.

She was honored for her commitment to improving the care of underrepresented patient populations, increasing awareness of DEI necessity, and building inclusive communities. In addition to these noteworthy achievements, she demonstrated scholarship on diversity, equity, and inclusion.

One way that Dr. Manning is fusing her love for diversity, equity, and inclusion with innovation is through her role as associate vice chair of the DEI department of Emory University’s School of Medicine. Within the department’s programs, resources and affinity groups, Dr. Manning leads a Virtual Visiting Clerkship Program for underrepresented medical students interested in pursuing a career in internal medicine.

“It includes coaching, mentorship, and diagnostic reasoning in an intimate and personal way,” she explained. “It makes me wish I were a medical student!”

In addition to her patient-centric and student-focused initiatives in Atlanta, Dr. Manning is an active contributor to SHM’s publications, including the Journal of Hospital Medicine and The Hospital Leader blog, in speaking out about racism in medicine, and other social inequities in health care. She even helped to lead a #JHMchat discussion on Twitter around these topics.

In fact, beyond being presented with the Diversity Leadership Award, she says that SHM and JHM have really demonstrated a strong commitment to diversity, equity, and inclusion.

“If you are a person with a lived experience or a person who is underrepresented in medicine, a lot of this work in diversity, equity, and inclusion never really had a name. It was called survival and looking out for each other,” Dr. Manning explained. “It’s exciting to be in this space now where there is focused, professional attention being given to something so important in our clinical and learning environments.”

SHM continues to reaffirm its longstanding commitment to diversity and inclusion and is dedicated to supporting and learning from its diverse member community. While SHM’s new Excellence in Diversity Leadership award is symbolic of a step in the right direction of change, Dr. Manning says that it is also an honor to be recognized for her areas of expertise and passion.

But that recognition moves far beyond this award. With so many more ways to connect with one another, Dr. Manning, a self-proclaimed optimist, says that one of the most exciting changes is centered on communication.

“For us to move the needle on anti-racism and representation, and to do more for our patients and colleagues, it must be a shared conversation. I feel particularly optimistic that I’m able to be more transparent than ever. I’m saying things to people whom I would have been too scared to say them to in the past.

“We’re hungry to grow and learn together,” she continued. “People are interacting in a more positive and constructive way. I’m so glad that we’re pushing diversity and you can see that a lot of people want to see us do better with this. We can continue to do better with this.”

SHM’s 2020-2021 Awards of Excellence nominations are now open with nine unique categories, including Excellence in Diversity, Equity, and Inclusion Leadership. If you have a peer or colleague in mind, like Dr. Manning, who has made exceptional contributions to DEI, or another important domain in hospital medicine, submit your nomination by Sept. 28, 2020.

“I have a feeling that this year has provided a lot of opportunity for people to emerge. The Committee is going to have a very, very tough job,” Dr. Manning said. “They are going to have some exciting nominations on their hands!”

Ms. Cowan is the marketing communications specialist at the Society of Hospital Medicine.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article

Facing systemic racism in health care: Inequities in medical education

Article Type
Changed
Fri, 12/04/2020 - 17:13
Vidyard Video

 

Resources:

Author and Disclosure Information

Dr. Levy is Clinical Professor, Obstetrics and Gynecology, George Washington University of Medicine and Health Sciences and Principal, The Levy Group LLC, Washington DC. She is a member of the OBG Management Board of Editors.  

Dr. Johnson is an Obstetrician-Gynecologist, UChicago Medicine.

Issue
OBG Management - 32(9)
Publications
Topics
Author and Disclosure Information

Dr. Levy is Clinical Professor, Obstetrics and Gynecology, George Washington University of Medicine and Health Sciences and Principal, The Levy Group LLC, Washington DC. She is a member of the OBG Management Board of Editors.  

Dr. Johnson is an Obstetrician-Gynecologist, UChicago Medicine.

Author and Disclosure Information

Dr. Levy is Clinical Professor, Obstetrics and Gynecology, George Washington University of Medicine and Health Sciences and Principal, The Levy Group LLC, Washington DC. She is a member of the OBG Management Board of Editors.  

Dr. Johnson is an Obstetrician-Gynecologist, UChicago Medicine.

Vidyard Video

 

Resources:

Vidyard Video

 

Resources:

Issue
OBG Management - 32(9)
Issue
OBG Management - 32(9)
Publications
Publications
Topics
Article Type
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 09/14/2020 - 16:15
Un-Gate On Date
Mon, 09/14/2020 - 16:15
Use ProPublica
CFC Schedule Remove Status
Mon, 09/14/2020 - 16:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article

In a time of two pandemics, a recommitment to work together

Article Type
Changed
Thu, 08/26/2021 - 16:00

Overwhelmed. As if we weren’t already overwhelmed. For decades, hospitalists have been on the forefront of improving acute care amidst a rapidly changing environment. These last few decades have seen tremendous advances in medicine, technology, safety culture, innovations in payment models, transformation in business models, and a rising tide of health care policy. There was never a year we didn’t face major change … and adapt to it. Then 2020 came upon us.

Dr. Jerome C. Siy

This year, we adapt to more than a score and 4 years’ worth of change.

The two pandemics that have come upon us are like tsunamis. And many of us are drowning. We know of threats of pandemics: influenza, Ebola, and the like. But SARS-CoV-2 is new and like no other. We live in fear and isolation, each and every day learning new information and debunking others. We also know of racial injustice and racism, implicit or explicit in our nation, whether we live it or just read of it. George Floyd’s death in my hometown marked another tsunami, a great realization in our nation, and a great unmasking of our denial.

Yet our country is not united.

Hospital medicine is not immune to this disunity. At a time that we are all treading water, staying afloat in our own hospitals and communities, confronting these issues beyond our immediate spheres of influence is overwhelming. We are impacted by these pandemics, personally and professionally. And admittedly, we can be both victim and perpetrator.

In the face of a novel infectious agent, medicine responded quickly and pushed us beyond our limits. We have developed new infection prevention guidelines. We worked creatively to solve PPE shortages. We fashioned new work flows and new care models. We accelerated telehealth applications. We expanded the boundaries on home-based programs and reached out to vulnerable elderly in congregate living – an isolation no older person should have to endure. We cared for our colleagues, neighbors, and family members who fell ill, some who recovered, and sadly, some who fell. We developed best-practice guidelines, research protocols, created new order sets, note templates, and documentation standards. We flexed into EDs, ICUs, and field hospitals. Amidst the turmoil, we took pay cuts and saw colleagues go on furlough. And still, we mentored leaders in our schools, churches, synagogues, mosques, and civic communities.

And just when we thought we could endure no more, on May 25, we witnessed a black man in Minneapolis killed by a policeman’s knee. The same knee that divided Americans when black American athletes knelt to protest the injustice their people have endured for centuries. A knee that has been confused for insolence, when it was meant for justice ... yes, justice, for all. So, in early June, around the nation in support of black lives we also knelt, for almost 9 minutes.

This was the third time I cried during the pandemics.

For many of us, structural racism in America had finally been unmasked. The nation protested and rioted for weeks, and some communities have continued. Indeed, these two pandemics are still surging.

Side by side COVID-19 case conferences we lay transparent data demonstrating health disparities that we have tolerated for so long. We have vowed to resource equity work, and we opened dialogue, not only with patients and communities of color, but also with colleagues of color – some ready and some not yet ready to share and relive the traumas of their past and their present.

And still, we are not united.

While we physically mask to prevent the spread of COVID-19, we must make efforts to unmask the truths of SARS-CoV-2, the failings of our health system, the richness of our communities of color, and the injustice in the fabric of our society. More importantly, we must work together to create solutions. While we have diverse interests and priorities, at SHM, we can find common ground with kindred spirits, enhance the role of our specialty, and advance the health of our patients.

Let’s not be mistaken. These pandemics add to a growing list of interwoven issues in our society. In 2018, I wrote a piece on the role of hospitalists in addressing rural health disparities.1 According to the Sheps Center for Health Services Research, 129 rural hospitals have closed since 2010, closures that have accelerated with the COVID-19 pandemic.2 More than ever, we must stand above our inner and outer conflicts and be united to promote the health of our nation during these pandemics, because “all policy is health policy.”3

Most SHM presidents and president-elects come in with a platform, a priority for the specialty and for the society. This year, the platform has chosen us. For 20 years, I have witnessed SHM be a workshop for our members to address the pressing needs of our specialty and our patients. In 2020, we’ve continued to see SHM as a workshop for our members and a tour de force addressing these pandemics, from just in time publications of research and perspectives in the Journal of Hospital Medicine, to webinars and open access education in the Learning Portal, to advocacy on Capitol Hill. All of that work has been informed by you and for you. While there is still so much to do, we need not be overwhelmed when we do it together.

A score and 4 years ago, Robert Wachter, MD, and Lee Goldman, MD, dubbed us “hospitalists.” A year later, our shared workshop was born. Through one name change and now our first CEO transition from Larry Wellikson, MD, to Eric Howell, MD, SHM will continue to be where hospitalists both adapt and shape our nation through solutions that put an end to these pandemics. Let’s recommit to this work together.

Dr. Siy is division medical director, hospital specialties, in the departments of hospital medicine and community senior and palliative care, at HealthPartners in Bloomington, Minn. He is president-elect of SHM.

Sources

1. Hardeman RR et al. Stolen Breaths. N Engl J Med. 2020 Jul 16;383:197-9.

2. Siy JC. Reviving Rural Health Care. The Hospitalist. 2018 Sep 24.

3. The Cecil G. Sheps Center For Health Services Research. Rural Hospital Closures. 2014. https://www.shepscenter.unc.edu/programs-projects/rural-health/rural-hospital-closures/

Publications
Topics
Sections

Overwhelmed. As if we weren’t already overwhelmed. For decades, hospitalists have been on the forefront of improving acute care amidst a rapidly changing environment. These last few decades have seen tremendous advances in medicine, technology, safety culture, innovations in payment models, transformation in business models, and a rising tide of health care policy. There was never a year we didn’t face major change … and adapt to it. Then 2020 came upon us.

Dr. Jerome C. Siy

This year, we adapt to more than a score and 4 years’ worth of change.

The two pandemics that have come upon us are like tsunamis. And many of us are drowning. We know of threats of pandemics: influenza, Ebola, and the like. But SARS-CoV-2 is new and like no other. We live in fear and isolation, each and every day learning new information and debunking others. We also know of racial injustice and racism, implicit or explicit in our nation, whether we live it or just read of it. George Floyd’s death in my hometown marked another tsunami, a great realization in our nation, and a great unmasking of our denial.

Yet our country is not united.

Hospital medicine is not immune to this disunity. At a time that we are all treading water, staying afloat in our own hospitals and communities, confronting these issues beyond our immediate spheres of influence is overwhelming. We are impacted by these pandemics, personally and professionally. And admittedly, we can be both victim and perpetrator.

In the face of a novel infectious agent, medicine responded quickly and pushed us beyond our limits. We have developed new infection prevention guidelines. We worked creatively to solve PPE shortages. We fashioned new work flows and new care models. We accelerated telehealth applications. We expanded the boundaries on home-based programs and reached out to vulnerable elderly in congregate living – an isolation no older person should have to endure. We cared for our colleagues, neighbors, and family members who fell ill, some who recovered, and sadly, some who fell. We developed best-practice guidelines, research protocols, created new order sets, note templates, and documentation standards. We flexed into EDs, ICUs, and field hospitals. Amidst the turmoil, we took pay cuts and saw colleagues go on furlough. And still, we mentored leaders in our schools, churches, synagogues, mosques, and civic communities.

And just when we thought we could endure no more, on May 25, we witnessed a black man in Minneapolis killed by a policeman’s knee. The same knee that divided Americans when black American athletes knelt to protest the injustice their people have endured for centuries. A knee that has been confused for insolence, when it was meant for justice ... yes, justice, for all. So, in early June, around the nation in support of black lives we also knelt, for almost 9 minutes.

This was the third time I cried during the pandemics.

For many of us, structural racism in America had finally been unmasked. The nation protested and rioted for weeks, and some communities have continued. Indeed, these two pandemics are still surging.

Side by side COVID-19 case conferences we lay transparent data demonstrating health disparities that we have tolerated for so long. We have vowed to resource equity work, and we opened dialogue, not only with patients and communities of color, but also with colleagues of color – some ready and some not yet ready to share and relive the traumas of their past and their present.

And still, we are not united.

While we physically mask to prevent the spread of COVID-19, we must make efforts to unmask the truths of SARS-CoV-2, the failings of our health system, the richness of our communities of color, and the injustice in the fabric of our society. More importantly, we must work together to create solutions. While we have diverse interests and priorities, at SHM, we can find common ground with kindred spirits, enhance the role of our specialty, and advance the health of our patients.

Let’s not be mistaken. These pandemics add to a growing list of interwoven issues in our society. In 2018, I wrote a piece on the role of hospitalists in addressing rural health disparities.1 According to the Sheps Center for Health Services Research, 129 rural hospitals have closed since 2010, closures that have accelerated with the COVID-19 pandemic.2 More than ever, we must stand above our inner and outer conflicts and be united to promote the health of our nation during these pandemics, because “all policy is health policy.”3

Most SHM presidents and president-elects come in with a platform, a priority for the specialty and for the society. This year, the platform has chosen us. For 20 years, I have witnessed SHM be a workshop for our members to address the pressing needs of our specialty and our patients. In 2020, we’ve continued to see SHM as a workshop for our members and a tour de force addressing these pandemics, from just in time publications of research and perspectives in the Journal of Hospital Medicine, to webinars and open access education in the Learning Portal, to advocacy on Capitol Hill. All of that work has been informed by you and for you. While there is still so much to do, we need not be overwhelmed when we do it together.

A score and 4 years ago, Robert Wachter, MD, and Lee Goldman, MD, dubbed us “hospitalists.” A year later, our shared workshop was born. Through one name change and now our first CEO transition from Larry Wellikson, MD, to Eric Howell, MD, SHM will continue to be where hospitalists both adapt and shape our nation through solutions that put an end to these pandemics. Let’s recommit to this work together.

Dr. Siy is division medical director, hospital specialties, in the departments of hospital medicine and community senior and palliative care, at HealthPartners in Bloomington, Minn. He is president-elect of SHM.

Sources

1. Hardeman RR et al. Stolen Breaths. N Engl J Med. 2020 Jul 16;383:197-9.

2. Siy JC. Reviving Rural Health Care. The Hospitalist. 2018 Sep 24.

3. The Cecil G. Sheps Center For Health Services Research. Rural Hospital Closures. 2014. https://www.shepscenter.unc.edu/programs-projects/rural-health/rural-hospital-closures/

Overwhelmed. As if we weren’t already overwhelmed. For decades, hospitalists have been on the forefront of improving acute care amidst a rapidly changing environment. These last few decades have seen tremendous advances in medicine, technology, safety culture, innovations in payment models, transformation in business models, and a rising tide of health care policy. There was never a year we didn’t face major change … and adapt to it. Then 2020 came upon us.

Dr. Jerome C. Siy

This year, we adapt to more than a score and 4 years’ worth of change.

The two pandemics that have come upon us are like tsunamis. And many of us are drowning. We know of threats of pandemics: influenza, Ebola, and the like. But SARS-CoV-2 is new and like no other. We live in fear and isolation, each and every day learning new information and debunking others. We also know of racial injustice and racism, implicit or explicit in our nation, whether we live it or just read of it. George Floyd’s death in my hometown marked another tsunami, a great realization in our nation, and a great unmasking of our denial.

Yet our country is not united.

Hospital medicine is not immune to this disunity. At a time that we are all treading water, staying afloat in our own hospitals and communities, confronting these issues beyond our immediate spheres of influence is overwhelming. We are impacted by these pandemics, personally and professionally. And admittedly, we can be both victim and perpetrator.

In the face of a novel infectious agent, medicine responded quickly and pushed us beyond our limits. We have developed new infection prevention guidelines. We worked creatively to solve PPE shortages. We fashioned new work flows and new care models. We accelerated telehealth applications. We expanded the boundaries on home-based programs and reached out to vulnerable elderly in congregate living – an isolation no older person should have to endure. We cared for our colleagues, neighbors, and family members who fell ill, some who recovered, and sadly, some who fell. We developed best-practice guidelines, research protocols, created new order sets, note templates, and documentation standards. We flexed into EDs, ICUs, and field hospitals. Amidst the turmoil, we took pay cuts and saw colleagues go on furlough. And still, we mentored leaders in our schools, churches, synagogues, mosques, and civic communities.

And just when we thought we could endure no more, on May 25, we witnessed a black man in Minneapolis killed by a policeman’s knee. The same knee that divided Americans when black American athletes knelt to protest the injustice their people have endured for centuries. A knee that has been confused for insolence, when it was meant for justice ... yes, justice, for all. So, in early June, around the nation in support of black lives we also knelt, for almost 9 minutes.

This was the third time I cried during the pandemics.

For many of us, structural racism in America had finally been unmasked. The nation protested and rioted for weeks, and some communities have continued. Indeed, these two pandemics are still surging.

Side by side COVID-19 case conferences we lay transparent data demonstrating health disparities that we have tolerated for so long. We have vowed to resource equity work, and we opened dialogue, not only with patients and communities of color, but also with colleagues of color – some ready and some not yet ready to share and relive the traumas of their past and their present.

And still, we are not united.

While we physically mask to prevent the spread of COVID-19, we must make efforts to unmask the truths of SARS-CoV-2, the failings of our health system, the richness of our communities of color, and the injustice in the fabric of our society. More importantly, we must work together to create solutions. While we have diverse interests and priorities, at SHM, we can find common ground with kindred spirits, enhance the role of our specialty, and advance the health of our patients.

Let’s not be mistaken. These pandemics add to a growing list of interwoven issues in our society. In 2018, I wrote a piece on the role of hospitalists in addressing rural health disparities.1 According to the Sheps Center for Health Services Research, 129 rural hospitals have closed since 2010, closures that have accelerated with the COVID-19 pandemic.2 More than ever, we must stand above our inner and outer conflicts and be united to promote the health of our nation during these pandemics, because “all policy is health policy.”3

Most SHM presidents and president-elects come in with a platform, a priority for the specialty and for the society. This year, the platform has chosen us. For 20 years, I have witnessed SHM be a workshop for our members to address the pressing needs of our specialty and our patients. In 2020, we’ve continued to see SHM as a workshop for our members and a tour de force addressing these pandemics, from just in time publications of research and perspectives in the Journal of Hospital Medicine, to webinars and open access education in the Learning Portal, to advocacy on Capitol Hill. All of that work has been informed by you and for you. While there is still so much to do, we need not be overwhelmed when we do it together.

A score and 4 years ago, Robert Wachter, MD, and Lee Goldman, MD, dubbed us “hospitalists.” A year later, our shared workshop was born. Through one name change and now our first CEO transition from Larry Wellikson, MD, to Eric Howell, MD, SHM will continue to be where hospitalists both adapt and shape our nation through solutions that put an end to these pandemics. Let’s recommit to this work together.

Dr. Siy is division medical director, hospital specialties, in the departments of hospital medicine and community senior and palliative care, at HealthPartners in Bloomington, Minn. He is president-elect of SHM.

Sources

1. Hardeman RR et al. Stolen Breaths. N Engl J Med. 2020 Jul 16;383:197-9.

2. Siy JC. Reviving Rural Health Care. The Hospitalist. 2018 Sep 24.

3. The Cecil G. Sheps Center For Health Services Research. Rural Hospital Closures. 2014. https://www.shepscenter.unc.edu/programs-projects/rural-health/rural-hospital-closures/

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article

Content Analysis of Psoriasis and Eczema Direct-to-Consumer Advertisements

Article Type
Changed
Thu, 10/29/2020 - 15:05

Direct-to-consumer (DTC) advertisements are an important and influential source of health-related information for Americans. In 1997, the US Food and Drug Administration (FDA) relaxed regulations and permitted DTC drug advertisements to be televised. Now, via television alone, the average American is exposed to more than 30 hours annually of DTC advertisements for drugs,1 which exceeds, by far, the amount of time the average American spends with his/her physician.2 The United States spends $9.6 billion on DTC advertisements per year, of which $605 million is spent exclusively on DTC advertisements for dermatologic conditions—one of the highest amounts of spending for DTC advertisements, second only to diabetes.3

The increase in advertising for dermatologic conditions is reflective of the rapid growth in the number of treatment options available for chronic skin diseases, especially psoriasis. Since 2004, 11 biologics and 1 oral medication were FDA approved for the treatment of moderate to severe psoriasis. Despite the expansion of treatment options for psoriasis, knowledge and understanding of psoriasis and its treatments generally are poor,4,5 and undertreatment of psoriasis continues to be common.6 Data also suggest existing age and racial disparities in psoriasis treatment in the United States, whereby patients who are older or Black are less likely to receive biologic therapies.7-9 Although the exact causes of these disparities remain unclear, one study found that Black patients with psoriasis were less familiar with biologics compared to White patients,10 which suggests that the racial disparity in biologic treatment of psoriasis could be due to less exposure to and thus recognition of biologics as treatments of psoriasis among Black patients.

Some data suggest that DTC advertisements may affect drug uptake by encouraging patients to request advertised medications from their medical providers.11,12 As such, DTC advertisements are a potentially important source of exposure and information for patients. However, is it possible that DTC advertisements also may contribute to widening knowledge gaps among certain populations, and thus treatment disparities, by neglecting certain groups and targeting others with their content? In an effort to answer this question, we performed an analysis of DTC advertisements for psoriasis and eczema with special attention to advertisement placement, character representation, and disease-related content. We specifically targeted advertisements for psoriasis and eczema, as advertisements for the former are rampant and advertisements for the latter are on the rise because of emerging therapies. We hypothesized that age and racial/ethnic diversity among advertisement characters is poor, and disease-related content is lacking.

Materials and Methods

Study Design and Sample
We performed a cross-sectional analysis of televised DTC advertisements for psoriasis and eczema over 14 consecutive days (July 1, 2018, to July 14, 2018). We accessed Nielsen’s top 10 lists, specifically Prime Broadcast Network TV-United States and Prime Broadcast Programs Among African-American, from June 2018 and identified the networks with the greatest potential exposure to American consumers: ABC, CBS, FOX, and NBC.13,14 Each day, programming aired from 5 pm to 11 pm EST was recorded on a random selection of 2 of 4 listed networks. No pair of networks was recorded for 2 consecutive days, and each day of the week was represented for each network.

The FDA identifies DTC advertisement types as product-claim, reminder, and help-seeking advertisements. Product-claim advertisements are required to include the following information for the drug of interest: name; at least 1 FDA-approved indication; the most notable risks; and reference to a toll-free telephone number, website, or print advertisement by which a detailed summary of risks and benefits can be accessed. Reminder advertisements include the name of the drug but no information about the drug’s use.15 Help-seeking advertisements describe a disease or condition without referencing a specific drug treatment. Product-claim, reminder, and help-seeking advertisements for psoriasis or eczema that aired during the recorded time frame were included for analysis; advertisements that aired during sporting events and special programming were excluded.

DTC Advertisement Coding
Advertisement placement (ie, network, day of the week, time, associated television program), type, and target disease were documented for all advertisements included in the study. The content of each unique advertisement for psoriasis and eczema also was documented electronically in REDCap (Research Electronic Data Capture) as follows: characteristics of affected individuals and disease-related content. Advertisement coding was performed independently by 2 graduate students (A.H. and C.W.). First, one-third of the advertisements were randomly selected to be coded by both students. Intercoder agreement between the 2 students was 95.3%. Coding disagreements were primarily due to misunderstanding of definitions and were resolved through consensus. Subsequently, the remaining advertisements were randomly distributed between the 2 students, and each advertisement was coded by 1 student.



Statistical Analysis
All data were summarized descriptively with counts and frequencies using Stata 15 (StataCorp).

Results

We identified 297 DTC advertisements addressing 25 different conditions during our study period. CBS, ABC, NBC, and FOX aired 44.4%, 26.3%, 24.4%, and 5.1% of advertisements, respectively. Overall, DTC advertisements were least likely to air on Saturdays and between the hours of 5 pm and 6 pm on any day. Product-claim advertisements accounted for 83.2% of DTC advertisements, 15.8% were help-seeking advertisements, and the remaining 1.0% were reminder advertisements. Advertisements for skin conditions represented 16.5% (n=49) of all DTC advertisements, of which 81.6% (n=40) were for psoriasis or eczema, while the other 18.4% (n=9) were for hyperhidrosis. In total, 13 advertisements for psoriasis and 27 advertisements for eczema were aired during the study period.

 

 

Psoriasis DTC Advertisements
There were 5 unique psoriasis DTC advertisements, all of which were product-claim advertisements, with 1 each for secukinumab (Cosentyx [Novartis]), ixekizumab (Taltz [Eli Lilly and Company]), and guselkumab (Tremfya [Janssen Biotech, Inc]), and 2 for adalimumab (Humira [AbbVie Inc]). The advertisements aired on ABC (n=5 [38.5%]), CBS (n=5 [38.5%]), and NBC (n=3 [23.1%]). Most advertisements aired on weekdays (61.5%) between 6 pm and 7 pm (69.2%) and during news programming (69.2%).



Psoriasis Character Portrayal and Disease-Related Content
We identified 81 main characters who were depicted as having psoriasis among all advertisements. Characteristics of the affected characters are summarized in the Table. All affected characters were perceived to be younger adults, and there was a slight female predominance (58.0% [47/81]). Most characters were perceived to be White (92.6% [75/81]). Black and Asian characters only represented 6.2% (5/81) and 1.2% (1/81) of all affected individuals, respectively. Notably, the advertisements that featured only White main characters were aired 2.75 times more frequently than the advertisements that included non-White characters.



Psoriasis was shown on the skin of at least 1 character in an obvious depiction (ie, did not require more than 1 viewing) in 84.6% (11/13) of the advertisements. Symptoms of psoriasis (communicated either verbally or visually) were included in only 15.4% (2/13) of advertisements. No advertisements included information on the epidemiology of (ie, prevalence, subpopulations at risk), risk factors for, pathophysiology of, or comorbid diseases associated with psoriasis.

Eczema DTC Advertisements
Among the 27 eczema advertisements aired, there were 4 unique advertisements, of which 3 were product-claim advertisements (all for crisaborole [Eucrisa (Pfizer Inc)]), and 1 was a help-seeking advertisement that was sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals. The advertisements aired on ABC (n=2 [7.4%]), CBS (n=17 [63.0%]), and NBC (n=8 [29.6%]). All advertisements aired on weekdays between 7 pm and 8 pm and during non-news programming.

Eczema Character Portrayal and Disease-Related Content
We identified 80 main characters who were depicted to be affected by eczema among all advertisements. Characteristics of the affected characters are summarized in the Table. Most of the affected characters were perceived to be White (53.8% [43/80]) and female (71.3% [57/80]). Other races depicted included Black (28.8% [23/80]) and Asian (17.5% [14/80]). Each unique eczema advertisement included at least 1 non-White main character. Most eczema main characters were perceived to be children (66.3% [53/80]), followed by younger adults (33.8% [27/80]). No infants, teenagers, or older adults were shown as being affected by eczema.



Skin manifestations of eczema were portrayed on at least 1 character in all of the advertisements; 77.8% (21/27) of the advertisements had at least 1 obvious depiction. Symptoms of eczema and the mechanism of disease (pathophysiology) were each included in 44.4% (12/27) of advertisements. This information was included exclusively in the single help-seeking advertisement, which also referenced a website for additional disease-related information. No advertisements included information on the epidemiology of, risk factors for, or comorbid diseases associated with eczema.

 

 

Comment

In our study of televised DTC advertisements for psoriasis and eczema in the United States, we identified underrepresentation of racial/ethnic minorities and specific age groups (older adults for psoriasis and all adults for eczema) across all advertisements. Although psoriasis is suggested to be less prevalent among minority patients (1.3%–1.9% among Black patients and 1.6% among Hispanic patients) compared to White patients (2%–4%),16,17 minority vs White representation in psoriasis DTC advertisements was disproportionately lower than population-based prevalence estimates. Direct-to-consumer advertisements for eczema included more minority characters than psoriasis advertisements; however, minority representation remained inadequate considering that childhood eczema is more prevalent among Black vs White children,18 and adult eczema is at least as prevalent among minority patients compared to White patients.19 Not only was minority representation in all advertisements poor, but advertisement placement also was suboptimal, particularly for reaching Black viewers. FOX network was home to 2 of the top 3 primetime broadcast programs among Black viewers around the study period,13 yet no DTC advertisements were aired on FOX. Together, our findings suggest inadequate patient reach of psoriasis and eczema DTC advertisements that, particularly in the case of psoriasis, mirror and may reinforce existing age and racial disparities in treatment5-7 and poor familiarity with biologics.10 A similar impact of eczema DTC advertisements on emerging eczema treatment patterns and potential treatment disparities also might be anticipated and is of concern.

The current literature regarding minority representation in DTC advertisements is mixed. Some studies report underrepresentation of Black and other minority patients across a variety of diseases.20 Other studies suggest that representation of Black patients, in particular, generally is adequate, except among select serious health conditions, and that advertisements depict tokenism or stereotypical roles for minorities.21 Our study provides new and specific insight about the state of racial/ethnic and age diversity, or lack thereof, in DTC advertisements for the skin conditions that currently are most commonly targeted—psoriasis and eczema. Although it remains unclear whether DTC advertisements are good or bad, existing data suggest that potential benefits of DTC advertisements include strengthening of patient-provider relationships, reduction of underdiagnosis and undertreatment of disease, and reduction of disease stigma.22 However, in our analyses, we found disease-specific factual content among all DTC advertisements to be sparse and obvious depictions of skin disease and symptoms to be uncommon, especially for psoriasis. As such, it seems unlikely that existing DTC advertisements for psoriasis and eczema can be expected to contribute to meaningful disease education, reduce underdiagnosis, and reduce the stigmatizing attitudes that have been documented for both skin diseases.23-25



Furthermore, it is important to consider our findings in light of the role that social identity theory plays in marketing. Social identity theory supports the idea that a person’s social identity (eg, age, gender, race/ethnicity) influences his/her behavior, perceptions, and performance.26 The principle of homophily—the tendency for individuals to have positive ties to those who are similar to themselves—is a critical concept in social identity theory and suggests that consumers are more likely to pay attention to and be influenced by sources perceived as similar to themselves.20 Thus, even if the potential benefits of DTC advertisements were to be realized for psoriasis and eczema, the lack of adequate minority and older adult representation raises concerns about whether these benefits would reach a diverse population and if the advertisements might further potentiate existing knowledge and treatment disparities.

Limitations
Our study is not without limitations. The sampling period was short and might not reflect advertisement content over a longer time course. We did not evaluate other potential sources of information, such as the Internet and social media. Nevertheless, televised DTC advertisements remain a major source of medical and drug information for the general public. We did not directly evaluate viewers’ reactions to the DTC advertisements of interest; however, other literature lends support to the significance of social identity theory and its impact on consumer behavior.26

Conclusion

Our study highlights a lost opportunity among psoriasis and eczema DTC advertisements for patient reach and disease education that may encourage existing and emerging knowledge and treatment disparities for both conditions. Our findings should serve as a call to action to pharmaceutical companies and other organizations involved in creating and supporting DTC advertisements for psoriasis and eczema to increase the educational content, diversify the depicted characters, and optimize advertisement placement.

References
  1. Brownfield ED, Bernhardt JM, Phan JL, et al. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. J Health Commun. 2004;9:491-497.
  2. Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42:1871-1894.
  3. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321:80-96.
  4. Lanigan SW, Farber EM. Patients’ knowledge of psoriasis: pilot study. Cutis. 1990;46:359-362.
  5. Renzi C, Di Pietro C, Tabolli S. Participation, satisfaction and knowledge level of patients with cutaneous psoriasis or psoriatic arthritis. Clin Exp Dermatol. 2011;36:885-888.
  6. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871-881.e871-830.
  7. Wu JJ, Lu M, Veverka KA, et al. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019;30:446-453.
  8. Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135:2955-2963.
  9. Kerr GS, Qaiyumi S, Richards J, et al. Psoriasis and psoriatic arthritis in African-American patients—the need to measure disease burden. Clin Rheumatol. 2015;34:1753-1759.
  10. Takeshita J, Eriksen WT, Raziano VT, et al. Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol. 2019;139:1672-1679.e1.
  11. Wu MH, Bartz D, Avorn J, et al. Trends in direct-to-consumer advertising of prescription contraceptives. Contraception. 2016;93:398-405.
  12. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? a survey in primary care environments with and without legal DTCA. CMAJ. 2003;169:405-412.
  13. Topten. Nielson website. https://www.nielsen.com/us/en/top-ten/. Accessed July 22, 2020.
  14. Leading ad supported broadcast and cable networks in the United States in 2019, by average number of viewers. Statistia website. https://www.statista.com/statistics/530119/tv-networks-viewers-usa/. Accessed July 22, 2020.
  15. Prescription drug advertisements. Electronic Code of Federal Regulations website. https://www.ecfr.gov/cgi-bin/text-idx?SID=d4f308e364578bda8e55a831638a26c6&mc=true&node=pt21.4.202&rgn=div5. Updated August 12, 2020. Accessed August 12, 2020.
  16. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23-26.
  17. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516.
  18. Centers for Disease Control and Prevention. National Center for Health Statistics, National Health Interview Survey, 2014. https://www.cdc.gov/nchs/data/health_policy/eczema_skin_problems_tables.pdf. Accessed July 22, 2020.
  19. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139:583-590.
  20. Welch Cline RJ, Young HN. Marketing drugs, marketing health care relationships: a content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Commun. 2004;16:131-157.
  21. Ball JG, Liang A, Lee WN. Representation of African Americans in direct-to-consumer pharmaceutical commercials: a content analysis with implications for health disparities. Health Mark Q. 2009;26:372-390.
  22. Ventola CL. Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? P T. 2011;36:669-674, 681-684.
  23. Pearl RL, Wan MT, Takeshita J, et al. Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students. J Am Acad Dermatol. 2019;80:1556-1563.
  24. Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2016;9:159-166.
  25. Wittkowski A, Richards HL, Griffiths CEM, et al. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res. 2004;57:195-200.
  26. Forehand MR, Deshpande R, Reed 2nd A. Identity salience and the influence of differential activation of the social self-schema on advertising response. J Appl Psychol. 2002;87:1086-1099.
Article PDF
Author and Disclosure Information

From the Perelman School of Medicine, University of Pennsylvania, Philadelphia. Ms. Wang and Dr. Takeshita are from the Department of Dermatology; Drs. Barg and Takeshita are from the Department of Biostatistics, Epidemiology and Informatics; and Dr. Barg also is from the Department of Family Medicine and Community Health.

Ms. Holmes was supported by the Dermatology Foundation Diversity Research Supplement Award. Dr. Takeshita is supported by the National Institute of Arthritis Musculoskeletal and Skin Diseases under Grant K23-AR068433, receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) for work that is unrelated to this study, and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Novartis. Ms. Williams, Ms. Wang, and Dr. Barg report no conflict of interest.

Correspondence: Junko Takeshita, MD, PhD, MSCE, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd, 7th Floor, South Tower, Office 728, Philadelphia, PA 19104 ([email protected]).

Issue
Cutis - 106(3)
Publications
Topics
Page Number
147-150
Sections
Author and Disclosure Information

From the Perelman School of Medicine, University of Pennsylvania, Philadelphia. Ms. Wang and Dr. Takeshita are from the Department of Dermatology; Drs. Barg and Takeshita are from the Department of Biostatistics, Epidemiology and Informatics; and Dr. Barg also is from the Department of Family Medicine and Community Health.

Ms. Holmes was supported by the Dermatology Foundation Diversity Research Supplement Award. Dr. Takeshita is supported by the National Institute of Arthritis Musculoskeletal and Skin Diseases under Grant K23-AR068433, receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) for work that is unrelated to this study, and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Novartis. Ms. Williams, Ms. Wang, and Dr. Barg report no conflict of interest.

Correspondence: Junko Takeshita, MD, PhD, MSCE, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd, 7th Floor, South Tower, Office 728, Philadelphia, PA 19104 ([email protected]).

Author and Disclosure Information

From the Perelman School of Medicine, University of Pennsylvania, Philadelphia. Ms. Wang and Dr. Takeshita are from the Department of Dermatology; Drs. Barg and Takeshita are from the Department of Biostatistics, Epidemiology and Informatics; and Dr. Barg also is from the Department of Family Medicine and Community Health.

Ms. Holmes was supported by the Dermatology Foundation Diversity Research Supplement Award. Dr. Takeshita is supported by the National Institute of Arthritis Musculoskeletal and Skin Diseases under Grant K23-AR068433, receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) for work that is unrelated to this study, and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Novartis. Ms. Williams, Ms. Wang, and Dr. Barg report no conflict of interest.

Correspondence: Junko Takeshita, MD, PhD, MSCE, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd, 7th Floor, South Tower, Office 728, Philadelphia, PA 19104 ([email protected]).

Article PDF
Article PDF

Direct-to-consumer (DTC) advertisements are an important and influential source of health-related information for Americans. In 1997, the US Food and Drug Administration (FDA) relaxed regulations and permitted DTC drug advertisements to be televised. Now, via television alone, the average American is exposed to more than 30 hours annually of DTC advertisements for drugs,1 which exceeds, by far, the amount of time the average American spends with his/her physician.2 The United States spends $9.6 billion on DTC advertisements per year, of which $605 million is spent exclusively on DTC advertisements for dermatologic conditions—one of the highest amounts of spending for DTC advertisements, second only to diabetes.3

The increase in advertising for dermatologic conditions is reflective of the rapid growth in the number of treatment options available for chronic skin diseases, especially psoriasis. Since 2004, 11 biologics and 1 oral medication were FDA approved for the treatment of moderate to severe psoriasis. Despite the expansion of treatment options for psoriasis, knowledge and understanding of psoriasis and its treatments generally are poor,4,5 and undertreatment of psoriasis continues to be common.6 Data also suggest existing age and racial disparities in psoriasis treatment in the United States, whereby patients who are older or Black are less likely to receive biologic therapies.7-9 Although the exact causes of these disparities remain unclear, one study found that Black patients with psoriasis were less familiar with biologics compared to White patients,10 which suggests that the racial disparity in biologic treatment of psoriasis could be due to less exposure to and thus recognition of biologics as treatments of psoriasis among Black patients.

Some data suggest that DTC advertisements may affect drug uptake by encouraging patients to request advertised medications from their medical providers.11,12 As such, DTC advertisements are a potentially important source of exposure and information for patients. However, is it possible that DTC advertisements also may contribute to widening knowledge gaps among certain populations, and thus treatment disparities, by neglecting certain groups and targeting others with their content? In an effort to answer this question, we performed an analysis of DTC advertisements for psoriasis and eczema with special attention to advertisement placement, character representation, and disease-related content. We specifically targeted advertisements for psoriasis and eczema, as advertisements for the former are rampant and advertisements for the latter are on the rise because of emerging therapies. We hypothesized that age and racial/ethnic diversity among advertisement characters is poor, and disease-related content is lacking.

Materials and Methods

Study Design and Sample
We performed a cross-sectional analysis of televised DTC advertisements for psoriasis and eczema over 14 consecutive days (July 1, 2018, to July 14, 2018). We accessed Nielsen’s top 10 lists, specifically Prime Broadcast Network TV-United States and Prime Broadcast Programs Among African-American, from June 2018 and identified the networks with the greatest potential exposure to American consumers: ABC, CBS, FOX, and NBC.13,14 Each day, programming aired from 5 pm to 11 pm EST was recorded on a random selection of 2 of 4 listed networks. No pair of networks was recorded for 2 consecutive days, and each day of the week was represented for each network.

The FDA identifies DTC advertisement types as product-claim, reminder, and help-seeking advertisements. Product-claim advertisements are required to include the following information for the drug of interest: name; at least 1 FDA-approved indication; the most notable risks; and reference to a toll-free telephone number, website, or print advertisement by which a detailed summary of risks and benefits can be accessed. Reminder advertisements include the name of the drug but no information about the drug’s use.15 Help-seeking advertisements describe a disease or condition without referencing a specific drug treatment. Product-claim, reminder, and help-seeking advertisements for psoriasis or eczema that aired during the recorded time frame were included for analysis; advertisements that aired during sporting events and special programming were excluded.

DTC Advertisement Coding
Advertisement placement (ie, network, day of the week, time, associated television program), type, and target disease were documented for all advertisements included in the study. The content of each unique advertisement for psoriasis and eczema also was documented electronically in REDCap (Research Electronic Data Capture) as follows: characteristics of affected individuals and disease-related content. Advertisement coding was performed independently by 2 graduate students (A.H. and C.W.). First, one-third of the advertisements were randomly selected to be coded by both students. Intercoder agreement between the 2 students was 95.3%. Coding disagreements were primarily due to misunderstanding of definitions and were resolved through consensus. Subsequently, the remaining advertisements were randomly distributed between the 2 students, and each advertisement was coded by 1 student.



Statistical Analysis
All data were summarized descriptively with counts and frequencies using Stata 15 (StataCorp).

Results

We identified 297 DTC advertisements addressing 25 different conditions during our study period. CBS, ABC, NBC, and FOX aired 44.4%, 26.3%, 24.4%, and 5.1% of advertisements, respectively. Overall, DTC advertisements were least likely to air on Saturdays and between the hours of 5 pm and 6 pm on any day. Product-claim advertisements accounted for 83.2% of DTC advertisements, 15.8% were help-seeking advertisements, and the remaining 1.0% were reminder advertisements. Advertisements for skin conditions represented 16.5% (n=49) of all DTC advertisements, of which 81.6% (n=40) were for psoriasis or eczema, while the other 18.4% (n=9) were for hyperhidrosis. In total, 13 advertisements for psoriasis and 27 advertisements for eczema were aired during the study period.

 

 

Psoriasis DTC Advertisements
There were 5 unique psoriasis DTC advertisements, all of which were product-claim advertisements, with 1 each for secukinumab (Cosentyx [Novartis]), ixekizumab (Taltz [Eli Lilly and Company]), and guselkumab (Tremfya [Janssen Biotech, Inc]), and 2 for adalimumab (Humira [AbbVie Inc]). The advertisements aired on ABC (n=5 [38.5%]), CBS (n=5 [38.5%]), and NBC (n=3 [23.1%]). Most advertisements aired on weekdays (61.5%) between 6 pm and 7 pm (69.2%) and during news programming (69.2%).



Psoriasis Character Portrayal and Disease-Related Content
We identified 81 main characters who were depicted as having psoriasis among all advertisements. Characteristics of the affected characters are summarized in the Table. All affected characters were perceived to be younger adults, and there was a slight female predominance (58.0% [47/81]). Most characters were perceived to be White (92.6% [75/81]). Black and Asian characters only represented 6.2% (5/81) and 1.2% (1/81) of all affected individuals, respectively. Notably, the advertisements that featured only White main characters were aired 2.75 times more frequently than the advertisements that included non-White characters.



Psoriasis was shown on the skin of at least 1 character in an obvious depiction (ie, did not require more than 1 viewing) in 84.6% (11/13) of the advertisements. Symptoms of psoriasis (communicated either verbally or visually) were included in only 15.4% (2/13) of advertisements. No advertisements included information on the epidemiology of (ie, prevalence, subpopulations at risk), risk factors for, pathophysiology of, or comorbid diseases associated with psoriasis.

Eczema DTC Advertisements
Among the 27 eczema advertisements aired, there were 4 unique advertisements, of which 3 were product-claim advertisements (all for crisaborole [Eucrisa (Pfizer Inc)]), and 1 was a help-seeking advertisement that was sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals. The advertisements aired on ABC (n=2 [7.4%]), CBS (n=17 [63.0%]), and NBC (n=8 [29.6%]). All advertisements aired on weekdays between 7 pm and 8 pm and during non-news programming.

Eczema Character Portrayal and Disease-Related Content
We identified 80 main characters who were depicted to be affected by eczema among all advertisements. Characteristics of the affected characters are summarized in the Table. Most of the affected characters were perceived to be White (53.8% [43/80]) and female (71.3% [57/80]). Other races depicted included Black (28.8% [23/80]) and Asian (17.5% [14/80]). Each unique eczema advertisement included at least 1 non-White main character. Most eczema main characters were perceived to be children (66.3% [53/80]), followed by younger adults (33.8% [27/80]). No infants, teenagers, or older adults were shown as being affected by eczema.



Skin manifestations of eczema were portrayed on at least 1 character in all of the advertisements; 77.8% (21/27) of the advertisements had at least 1 obvious depiction. Symptoms of eczema and the mechanism of disease (pathophysiology) were each included in 44.4% (12/27) of advertisements. This information was included exclusively in the single help-seeking advertisement, which also referenced a website for additional disease-related information. No advertisements included information on the epidemiology of, risk factors for, or comorbid diseases associated with eczema.

 

 

Comment

In our study of televised DTC advertisements for psoriasis and eczema in the United States, we identified underrepresentation of racial/ethnic minorities and specific age groups (older adults for psoriasis and all adults for eczema) across all advertisements. Although psoriasis is suggested to be less prevalent among minority patients (1.3%–1.9% among Black patients and 1.6% among Hispanic patients) compared to White patients (2%–4%),16,17 minority vs White representation in psoriasis DTC advertisements was disproportionately lower than population-based prevalence estimates. Direct-to-consumer advertisements for eczema included more minority characters than psoriasis advertisements; however, minority representation remained inadequate considering that childhood eczema is more prevalent among Black vs White children,18 and adult eczema is at least as prevalent among minority patients compared to White patients.19 Not only was minority representation in all advertisements poor, but advertisement placement also was suboptimal, particularly for reaching Black viewers. FOX network was home to 2 of the top 3 primetime broadcast programs among Black viewers around the study period,13 yet no DTC advertisements were aired on FOX. Together, our findings suggest inadequate patient reach of psoriasis and eczema DTC advertisements that, particularly in the case of psoriasis, mirror and may reinforce existing age and racial disparities in treatment5-7 and poor familiarity with biologics.10 A similar impact of eczema DTC advertisements on emerging eczema treatment patterns and potential treatment disparities also might be anticipated and is of concern.

The current literature regarding minority representation in DTC advertisements is mixed. Some studies report underrepresentation of Black and other minority patients across a variety of diseases.20 Other studies suggest that representation of Black patients, in particular, generally is adequate, except among select serious health conditions, and that advertisements depict tokenism or stereotypical roles for minorities.21 Our study provides new and specific insight about the state of racial/ethnic and age diversity, or lack thereof, in DTC advertisements for the skin conditions that currently are most commonly targeted—psoriasis and eczema. Although it remains unclear whether DTC advertisements are good or bad, existing data suggest that potential benefits of DTC advertisements include strengthening of patient-provider relationships, reduction of underdiagnosis and undertreatment of disease, and reduction of disease stigma.22 However, in our analyses, we found disease-specific factual content among all DTC advertisements to be sparse and obvious depictions of skin disease and symptoms to be uncommon, especially for psoriasis. As such, it seems unlikely that existing DTC advertisements for psoriasis and eczema can be expected to contribute to meaningful disease education, reduce underdiagnosis, and reduce the stigmatizing attitudes that have been documented for both skin diseases.23-25



Furthermore, it is important to consider our findings in light of the role that social identity theory plays in marketing. Social identity theory supports the idea that a person’s social identity (eg, age, gender, race/ethnicity) influences his/her behavior, perceptions, and performance.26 The principle of homophily—the tendency for individuals to have positive ties to those who are similar to themselves—is a critical concept in social identity theory and suggests that consumers are more likely to pay attention to and be influenced by sources perceived as similar to themselves.20 Thus, even if the potential benefits of DTC advertisements were to be realized for psoriasis and eczema, the lack of adequate minority and older adult representation raises concerns about whether these benefits would reach a diverse population and if the advertisements might further potentiate existing knowledge and treatment disparities.

Limitations
Our study is not without limitations. The sampling period was short and might not reflect advertisement content over a longer time course. We did not evaluate other potential sources of information, such as the Internet and social media. Nevertheless, televised DTC advertisements remain a major source of medical and drug information for the general public. We did not directly evaluate viewers’ reactions to the DTC advertisements of interest; however, other literature lends support to the significance of social identity theory and its impact on consumer behavior.26

Conclusion

Our study highlights a lost opportunity among psoriasis and eczema DTC advertisements for patient reach and disease education that may encourage existing and emerging knowledge and treatment disparities for both conditions. Our findings should serve as a call to action to pharmaceutical companies and other organizations involved in creating and supporting DTC advertisements for psoriasis and eczema to increase the educational content, diversify the depicted characters, and optimize advertisement placement.

Direct-to-consumer (DTC) advertisements are an important and influential source of health-related information for Americans. In 1997, the US Food and Drug Administration (FDA) relaxed regulations and permitted DTC drug advertisements to be televised. Now, via television alone, the average American is exposed to more than 30 hours annually of DTC advertisements for drugs,1 which exceeds, by far, the amount of time the average American spends with his/her physician.2 The United States spends $9.6 billion on DTC advertisements per year, of which $605 million is spent exclusively on DTC advertisements for dermatologic conditions—one of the highest amounts of spending for DTC advertisements, second only to diabetes.3

The increase in advertising for dermatologic conditions is reflective of the rapid growth in the number of treatment options available for chronic skin diseases, especially psoriasis. Since 2004, 11 biologics and 1 oral medication were FDA approved for the treatment of moderate to severe psoriasis. Despite the expansion of treatment options for psoriasis, knowledge and understanding of psoriasis and its treatments generally are poor,4,5 and undertreatment of psoriasis continues to be common.6 Data also suggest existing age and racial disparities in psoriasis treatment in the United States, whereby patients who are older or Black are less likely to receive biologic therapies.7-9 Although the exact causes of these disparities remain unclear, one study found that Black patients with psoriasis were less familiar with biologics compared to White patients,10 which suggests that the racial disparity in biologic treatment of psoriasis could be due to less exposure to and thus recognition of biologics as treatments of psoriasis among Black patients.

Some data suggest that DTC advertisements may affect drug uptake by encouraging patients to request advertised medications from their medical providers.11,12 As such, DTC advertisements are a potentially important source of exposure and information for patients. However, is it possible that DTC advertisements also may contribute to widening knowledge gaps among certain populations, and thus treatment disparities, by neglecting certain groups and targeting others with their content? In an effort to answer this question, we performed an analysis of DTC advertisements for psoriasis and eczema with special attention to advertisement placement, character representation, and disease-related content. We specifically targeted advertisements for psoriasis and eczema, as advertisements for the former are rampant and advertisements for the latter are on the rise because of emerging therapies. We hypothesized that age and racial/ethnic diversity among advertisement characters is poor, and disease-related content is lacking.

Materials and Methods

Study Design and Sample
We performed a cross-sectional analysis of televised DTC advertisements for psoriasis and eczema over 14 consecutive days (July 1, 2018, to July 14, 2018). We accessed Nielsen’s top 10 lists, specifically Prime Broadcast Network TV-United States and Prime Broadcast Programs Among African-American, from June 2018 and identified the networks with the greatest potential exposure to American consumers: ABC, CBS, FOX, and NBC.13,14 Each day, programming aired from 5 pm to 11 pm EST was recorded on a random selection of 2 of 4 listed networks. No pair of networks was recorded for 2 consecutive days, and each day of the week was represented for each network.

The FDA identifies DTC advertisement types as product-claim, reminder, and help-seeking advertisements. Product-claim advertisements are required to include the following information for the drug of interest: name; at least 1 FDA-approved indication; the most notable risks; and reference to a toll-free telephone number, website, or print advertisement by which a detailed summary of risks and benefits can be accessed. Reminder advertisements include the name of the drug but no information about the drug’s use.15 Help-seeking advertisements describe a disease or condition without referencing a specific drug treatment. Product-claim, reminder, and help-seeking advertisements for psoriasis or eczema that aired during the recorded time frame were included for analysis; advertisements that aired during sporting events and special programming were excluded.

DTC Advertisement Coding
Advertisement placement (ie, network, day of the week, time, associated television program), type, and target disease were documented for all advertisements included in the study. The content of each unique advertisement for psoriasis and eczema also was documented electronically in REDCap (Research Electronic Data Capture) as follows: characteristics of affected individuals and disease-related content. Advertisement coding was performed independently by 2 graduate students (A.H. and C.W.). First, one-third of the advertisements were randomly selected to be coded by both students. Intercoder agreement between the 2 students was 95.3%. Coding disagreements were primarily due to misunderstanding of definitions and were resolved through consensus. Subsequently, the remaining advertisements were randomly distributed between the 2 students, and each advertisement was coded by 1 student.



Statistical Analysis
All data were summarized descriptively with counts and frequencies using Stata 15 (StataCorp).

Results

We identified 297 DTC advertisements addressing 25 different conditions during our study period. CBS, ABC, NBC, and FOX aired 44.4%, 26.3%, 24.4%, and 5.1% of advertisements, respectively. Overall, DTC advertisements were least likely to air on Saturdays and between the hours of 5 pm and 6 pm on any day. Product-claim advertisements accounted for 83.2% of DTC advertisements, 15.8% were help-seeking advertisements, and the remaining 1.0% were reminder advertisements. Advertisements for skin conditions represented 16.5% (n=49) of all DTC advertisements, of which 81.6% (n=40) were for psoriasis or eczema, while the other 18.4% (n=9) were for hyperhidrosis. In total, 13 advertisements for psoriasis and 27 advertisements for eczema were aired during the study period.

 

 

Psoriasis DTC Advertisements
There were 5 unique psoriasis DTC advertisements, all of which were product-claim advertisements, with 1 each for secukinumab (Cosentyx [Novartis]), ixekizumab (Taltz [Eli Lilly and Company]), and guselkumab (Tremfya [Janssen Biotech, Inc]), and 2 for adalimumab (Humira [AbbVie Inc]). The advertisements aired on ABC (n=5 [38.5%]), CBS (n=5 [38.5%]), and NBC (n=3 [23.1%]). Most advertisements aired on weekdays (61.5%) between 6 pm and 7 pm (69.2%) and during news programming (69.2%).



Psoriasis Character Portrayal and Disease-Related Content
We identified 81 main characters who were depicted as having psoriasis among all advertisements. Characteristics of the affected characters are summarized in the Table. All affected characters were perceived to be younger adults, and there was a slight female predominance (58.0% [47/81]). Most characters were perceived to be White (92.6% [75/81]). Black and Asian characters only represented 6.2% (5/81) and 1.2% (1/81) of all affected individuals, respectively. Notably, the advertisements that featured only White main characters were aired 2.75 times more frequently than the advertisements that included non-White characters.



Psoriasis was shown on the skin of at least 1 character in an obvious depiction (ie, did not require more than 1 viewing) in 84.6% (11/13) of the advertisements. Symptoms of psoriasis (communicated either verbally or visually) were included in only 15.4% (2/13) of advertisements. No advertisements included information on the epidemiology of (ie, prevalence, subpopulations at risk), risk factors for, pathophysiology of, or comorbid diseases associated with psoriasis.

Eczema DTC Advertisements
Among the 27 eczema advertisements aired, there were 4 unique advertisements, of which 3 were product-claim advertisements (all for crisaborole [Eucrisa (Pfizer Inc)]), and 1 was a help-seeking advertisement that was sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals. The advertisements aired on ABC (n=2 [7.4%]), CBS (n=17 [63.0%]), and NBC (n=8 [29.6%]). All advertisements aired on weekdays between 7 pm and 8 pm and during non-news programming.

Eczema Character Portrayal and Disease-Related Content
We identified 80 main characters who were depicted to be affected by eczema among all advertisements. Characteristics of the affected characters are summarized in the Table. Most of the affected characters were perceived to be White (53.8% [43/80]) and female (71.3% [57/80]). Other races depicted included Black (28.8% [23/80]) and Asian (17.5% [14/80]). Each unique eczema advertisement included at least 1 non-White main character. Most eczema main characters were perceived to be children (66.3% [53/80]), followed by younger adults (33.8% [27/80]). No infants, teenagers, or older adults were shown as being affected by eczema.



Skin manifestations of eczema were portrayed on at least 1 character in all of the advertisements; 77.8% (21/27) of the advertisements had at least 1 obvious depiction. Symptoms of eczema and the mechanism of disease (pathophysiology) were each included in 44.4% (12/27) of advertisements. This information was included exclusively in the single help-seeking advertisement, which also referenced a website for additional disease-related information. No advertisements included information on the epidemiology of, risk factors for, or comorbid diseases associated with eczema.

 

 

Comment

In our study of televised DTC advertisements for psoriasis and eczema in the United States, we identified underrepresentation of racial/ethnic minorities and specific age groups (older adults for psoriasis and all adults for eczema) across all advertisements. Although psoriasis is suggested to be less prevalent among minority patients (1.3%–1.9% among Black patients and 1.6% among Hispanic patients) compared to White patients (2%–4%),16,17 minority vs White representation in psoriasis DTC advertisements was disproportionately lower than population-based prevalence estimates. Direct-to-consumer advertisements for eczema included more minority characters than psoriasis advertisements; however, minority representation remained inadequate considering that childhood eczema is more prevalent among Black vs White children,18 and adult eczema is at least as prevalent among minority patients compared to White patients.19 Not only was minority representation in all advertisements poor, but advertisement placement also was suboptimal, particularly for reaching Black viewers. FOX network was home to 2 of the top 3 primetime broadcast programs among Black viewers around the study period,13 yet no DTC advertisements were aired on FOX. Together, our findings suggest inadequate patient reach of psoriasis and eczema DTC advertisements that, particularly in the case of psoriasis, mirror and may reinforce existing age and racial disparities in treatment5-7 and poor familiarity with biologics.10 A similar impact of eczema DTC advertisements on emerging eczema treatment patterns and potential treatment disparities also might be anticipated and is of concern.

The current literature regarding minority representation in DTC advertisements is mixed. Some studies report underrepresentation of Black and other minority patients across a variety of diseases.20 Other studies suggest that representation of Black patients, in particular, generally is adequate, except among select serious health conditions, and that advertisements depict tokenism or stereotypical roles for minorities.21 Our study provides new and specific insight about the state of racial/ethnic and age diversity, or lack thereof, in DTC advertisements for the skin conditions that currently are most commonly targeted—psoriasis and eczema. Although it remains unclear whether DTC advertisements are good or bad, existing data suggest that potential benefits of DTC advertisements include strengthening of patient-provider relationships, reduction of underdiagnosis and undertreatment of disease, and reduction of disease stigma.22 However, in our analyses, we found disease-specific factual content among all DTC advertisements to be sparse and obvious depictions of skin disease and symptoms to be uncommon, especially for psoriasis. As such, it seems unlikely that existing DTC advertisements for psoriasis and eczema can be expected to contribute to meaningful disease education, reduce underdiagnosis, and reduce the stigmatizing attitudes that have been documented for both skin diseases.23-25



Furthermore, it is important to consider our findings in light of the role that social identity theory plays in marketing. Social identity theory supports the idea that a person’s social identity (eg, age, gender, race/ethnicity) influences his/her behavior, perceptions, and performance.26 The principle of homophily—the tendency for individuals to have positive ties to those who are similar to themselves—is a critical concept in social identity theory and suggests that consumers are more likely to pay attention to and be influenced by sources perceived as similar to themselves.20 Thus, even if the potential benefits of DTC advertisements were to be realized for psoriasis and eczema, the lack of adequate minority and older adult representation raises concerns about whether these benefits would reach a diverse population and if the advertisements might further potentiate existing knowledge and treatment disparities.

Limitations
Our study is not without limitations. The sampling period was short and might not reflect advertisement content over a longer time course. We did not evaluate other potential sources of information, such as the Internet and social media. Nevertheless, televised DTC advertisements remain a major source of medical and drug information for the general public. We did not directly evaluate viewers’ reactions to the DTC advertisements of interest; however, other literature lends support to the significance of social identity theory and its impact on consumer behavior.26

Conclusion

Our study highlights a lost opportunity among psoriasis and eczema DTC advertisements for patient reach and disease education that may encourage existing and emerging knowledge and treatment disparities for both conditions. Our findings should serve as a call to action to pharmaceutical companies and other organizations involved in creating and supporting DTC advertisements for psoriasis and eczema to increase the educational content, diversify the depicted characters, and optimize advertisement placement.

References
  1. Brownfield ED, Bernhardt JM, Phan JL, et al. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. J Health Commun. 2004;9:491-497.
  2. Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42:1871-1894.
  3. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321:80-96.
  4. Lanigan SW, Farber EM. Patients’ knowledge of psoriasis: pilot study. Cutis. 1990;46:359-362.
  5. Renzi C, Di Pietro C, Tabolli S. Participation, satisfaction and knowledge level of patients with cutaneous psoriasis or psoriatic arthritis. Clin Exp Dermatol. 2011;36:885-888.
  6. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871-881.e871-830.
  7. Wu JJ, Lu M, Veverka KA, et al. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019;30:446-453.
  8. Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135:2955-2963.
  9. Kerr GS, Qaiyumi S, Richards J, et al. Psoriasis and psoriatic arthritis in African-American patients—the need to measure disease burden. Clin Rheumatol. 2015;34:1753-1759.
  10. Takeshita J, Eriksen WT, Raziano VT, et al. Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol. 2019;139:1672-1679.e1.
  11. Wu MH, Bartz D, Avorn J, et al. Trends in direct-to-consumer advertising of prescription contraceptives. Contraception. 2016;93:398-405.
  12. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? a survey in primary care environments with and without legal DTCA. CMAJ. 2003;169:405-412.
  13. Topten. Nielson website. https://www.nielsen.com/us/en/top-ten/. Accessed July 22, 2020.
  14. Leading ad supported broadcast and cable networks in the United States in 2019, by average number of viewers. Statistia website. https://www.statista.com/statistics/530119/tv-networks-viewers-usa/. Accessed July 22, 2020.
  15. Prescription drug advertisements. Electronic Code of Federal Regulations website. https://www.ecfr.gov/cgi-bin/text-idx?SID=d4f308e364578bda8e55a831638a26c6&mc=true&node=pt21.4.202&rgn=div5. Updated August 12, 2020. Accessed August 12, 2020.
  16. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23-26.
  17. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516.
  18. Centers for Disease Control and Prevention. National Center for Health Statistics, National Health Interview Survey, 2014. https://www.cdc.gov/nchs/data/health_policy/eczema_skin_problems_tables.pdf. Accessed July 22, 2020.
  19. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139:583-590.
  20. Welch Cline RJ, Young HN. Marketing drugs, marketing health care relationships: a content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Commun. 2004;16:131-157.
  21. Ball JG, Liang A, Lee WN. Representation of African Americans in direct-to-consumer pharmaceutical commercials: a content analysis with implications for health disparities. Health Mark Q. 2009;26:372-390.
  22. Ventola CL. Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? P T. 2011;36:669-674, 681-684.
  23. Pearl RL, Wan MT, Takeshita J, et al. Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students. J Am Acad Dermatol. 2019;80:1556-1563.
  24. Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2016;9:159-166.
  25. Wittkowski A, Richards HL, Griffiths CEM, et al. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res. 2004;57:195-200.
  26. Forehand MR, Deshpande R, Reed 2nd A. Identity salience and the influence of differential activation of the social self-schema on advertising response. J Appl Psychol. 2002;87:1086-1099.
References
  1. Brownfield ED, Bernhardt JM, Phan JL, et al. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. J Health Commun. 2004;9:491-497.
  2. Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42:1871-1894.
  3. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321:80-96.
  4. Lanigan SW, Farber EM. Patients’ knowledge of psoriasis: pilot study. Cutis. 1990;46:359-362.
  5. Renzi C, Di Pietro C, Tabolli S. Participation, satisfaction and knowledge level of patients with cutaneous psoriasis or psoriatic arthritis. Clin Exp Dermatol. 2011;36:885-888.
  6. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871-881.e871-830.
  7. Wu JJ, Lu M, Veverka KA, et al. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019;30:446-453.
  8. Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135:2955-2963.
  9. Kerr GS, Qaiyumi S, Richards J, et al. Psoriasis and psoriatic arthritis in African-American patients—the need to measure disease burden. Clin Rheumatol. 2015;34:1753-1759.
  10. Takeshita J, Eriksen WT, Raziano VT, et al. Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol. 2019;139:1672-1679.e1.
  11. Wu MH, Bartz D, Avorn J, et al. Trends in direct-to-consumer advertising of prescription contraceptives. Contraception. 2016;93:398-405.
  12. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? a survey in primary care environments with and without legal DTCA. CMAJ. 2003;169:405-412.
  13. Topten. Nielson website. https://www.nielsen.com/us/en/top-ten/. Accessed July 22, 2020.
  14. Leading ad supported broadcast and cable networks in the United States in 2019, by average number of viewers. Statistia website. https://www.statista.com/statistics/530119/tv-networks-viewers-usa/. Accessed July 22, 2020.
  15. Prescription drug advertisements. Electronic Code of Federal Regulations website. https://www.ecfr.gov/cgi-bin/text-idx?SID=d4f308e364578bda8e55a831638a26c6&mc=true&node=pt21.4.202&rgn=div5. Updated August 12, 2020. Accessed August 12, 2020.
  16. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23-26.
  17. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516.
  18. Centers for Disease Control and Prevention. National Center for Health Statistics, National Health Interview Survey, 2014. https://www.cdc.gov/nchs/data/health_policy/eczema_skin_problems_tables.pdf. Accessed July 22, 2020.
  19. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139:583-590.
  20. Welch Cline RJ, Young HN. Marketing drugs, marketing health care relationships: a content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Commun. 2004;16:131-157.
  21. Ball JG, Liang A, Lee WN. Representation of African Americans in direct-to-consumer pharmaceutical commercials: a content analysis with implications for health disparities. Health Mark Q. 2009;26:372-390.
  22. Ventola CL. Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? P T. 2011;36:669-674, 681-684.
  23. Pearl RL, Wan MT, Takeshita J, et al. Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students. J Am Acad Dermatol. 2019;80:1556-1563.
  24. Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2016;9:159-166.
  25. Wittkowski A, Richards HL, Griffiths CEM, et al. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res. 2004;57:195-200.
  26. Forehand MR, Deshpande R, Reed 2nd A. Identity salience and the influence of differential activation of the social self-schema on advertising response. J Appl Psychol. 2002;87:1086-1099.
Issue
Cutis - 106(3)
Issue
Cutis - 106(3)
Page Number
147-150
Page Number
147-150
Publications
Publications
Topics
Article Type
Sections
Inside the Article

Practice Points

  • Racial/ethnic minorities and older adults are underrepresented in direct-to-consumer (DTC) advertisements for psoriasis and eczema.
  • Character representation in psoriasis DTC advertisements, in particular, mirrors existing age and racial disparities in treatment with biologics.
  • Disease-specific factual content was sparse, and obvious depictions of skin disease and symptoms were uncommon, especially among psoriasis DTC advertisements.
  • Dermatologists should be aware of these deficiencies in psoriasis and eczema DTC advertisements and take care not to further reinforce existing knowledge gaps and inequitable treatment patterns among patients.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media

PHM20 Virtual: Impact of racism in medicine

Article Type
Changed
Thu, 10/29/2020 - 14:11

 

Presenters

Michael Bryant, MD – Children’s Hospital of Los Angeles

Kimberly Manning, MD – Emory University, Atlanta

Kimberly Reynolds, MD – University of Miami

Samir Shah, MD, MSCE, MHM – Cincinnati Children’s Hospital

Ndidi Unaka, MD, MEd – Cincinnati Children’s Hospital

Moderator

Erin Shaughnessy, MD – Phoenix Children’s Hospital

Session summary

This session was devoted to a discussion about how pediatric hospital medicine (PHM) as a field can address racism in medicine. The structural inequity rooted in poverty, housing problems, and differential education represents the essential social determinant of health. No longer can pediatric hospitalists neglect or be in denial of the crucial role that race plays in propagating further inequalities in our society and at our workplace. Historically Black people were exploited in research and still are disproportionately affected when it comes to infant prematurity and mortality, asthma, pain treatments, and so on. The pediatric hospitalist must explore and understand the reasons behind nonadherence and noncompliance among Black patients and always seek to understand before criticizing.

Dr. Mirna Giordano

Within learning environments, we must improve how to “autocorrect” and proactively work on our own biases. Dr. Bryant pointed out that each institution has the responsibility to build on the civil rights movement and seize the moment to create a robust response to the inequities manifested during the COVID-19 epidemic, as well as the events following the deaths of George Floyd, Breonna Taylor, Ahmoud Arbery, and many others. Dr. Shah called on the PHM community to take on that obligation by “stepping into the tension,” as Mark Shapiro, MD, has suggested in a conversation/podcast with Dr. Unaka.

As pediatric hospitalists, we will have to show up both individually and as constituents of institutions to address racism by specific projects looking at all data relevant for racism rather than race in quality and safety – thereby amplifying the voices of our Black patients and families, remarked Dr. Unaka. There was a brief reflection on the use of the word “allies” by Dr. Manning and Dr. Reynolds to remind the more than 200 session participants that a bidirectional framework of this process is crucial and that there is a clear need for a partnership to a common goal that should start by “a laydown of privilege of those who have it” to establish equal playing fields once and for all.

Dr. Bryant encouraged a deliberate and early thoughtful process to identify those with opportunities and help young Black people explore journeys in medicine and increase diversity among PHM faculty. Dr. Manning reminded the audience of the power that relationships have and hold in our lives, and not only those of mentors and mentees, but also relationships among all of us as humans. As with those simple situations in which we mess up and have to be able to admit it, apologize for it, and learn to move on, this requires also showing up as a mentee, articulating one’s needs, and learning to break the habits rooted in biases. Dr. Unaka warned against stereotypes and reminded us to look deeper and understand better all of our learners and their blind spots, as well as our own.
 

Key takeaways

  • The field of PHM must recognize the role that race plays in propagating inequalities.
  • Learning and mentorship environments have to be assessed for the safety of all learners and adjusted to correct (and autocorrect) as many biases as possible.
  • Institutions must assume responsibilities to establish a conscious, robust response to injustice and racism in a timely and specific manner.
  • Further research efforts must be made to address racism, rather than race.
  • The PHM community must show up to create a new, healthy, and deliberate bidirectional framework to endorse and support diversity.

Dr. Giordano is assistant professor of pediatrics at Columbia University and a pediatric hospitalist at NewYork–Presbyterian Morgan Stanley Children’s Hospital, both in New York, with an interest in surgical comanagement. She serves on the Society of Hospital Medicine’s Pediatric Special Interest Group Executive Committee and is the chair of the Education Subcommittee. She is also an advisory board member for the New York/Westchester SHM Chapter.

Publications
Topics
Sections

 

Presenters

Michael Bryant, MD – Children’s Hospital of Los Angeles

Kimberly Manning, MD – Emory University, Atlanta

Kimberly Reynolds, MD – University of Miami

Samir Shah, MD, MSCE, MHM – Cincinnati Children’s Hospital

Ndidi Unaka, MD, MEd – Cincinnati Children’s Hospital

Moderator

Erin Shaughnessy, MD – Phoenix Children’s Hospital

Session summary

This session was devoted to a discussion about how pediatric hospital medicine (PHM) as a field can address racism in medicine. The structural inequity rooted in poverty, housing problems, and differential education represents the essential social determinant of health. No longer can pediatric hospitalists neglect or be in denial of the crucial role that race plays in propagating further inequalities in our society and at our workplace. Historically Black people were exploited in research and still are disproportionately affected when it comes to infant prematurity and mortality, asthma, pain treatments, and so on. The pediatric hospitalist must explore and understand the reasons behind nonadherence and noncompliance among Black patients and always seek to understand before criticizing.

Dr. Mirna Giordano

Within learning environments, we must improve how to “autocorrect” and proactively work on our own biases. Dr. Bryant pointed out that each institution has the responsibility to build on the civil rights movement and seize the moment to create a robust response to the inequities manifested during the COVID-19 epidemic, as well as the events following the deaths of George Floyd, Breonna Taylor, Ahmoud Arbery, and many others. Dr. Shah called on the PHM community to take on that obligation by “stepping into the tension,” as Mark Shapiro, MD, has suggested in a conversation/podcast with Dr. Unaka.

As pediatric hospitalists, we will have to show up both individually and as constituents of institutions to address racism by specific projects looking at all data relevant for racism rather than race in quality and safety – thereby amplifying the voices of our Black patients and families, remarked Dr. Unaka. There was a brief reflection on the use of the word “allies” by Dr. Manning and Dr. Reynolds to remind the more than 200 session participants that a bidirectional framework of this process is crucial and that there is a clear need for a partnership to a common goal that should start by “a laydown of privilege of those who have it” to establish equal playing fields once and for all.

Dr. Bryant encouraged a deliberate and early thoughtful process to identify those with opportunities and help young Black people explore journeys in medicine and increase diversity among PHM faculty. Dr. Manning reminded the audience of the power that relationships have and hold in our lives, and not only those of mentors and mentees, but also relationships among all of us as humans. As with those simple situations in which we mess up and have to be able to admit it, apologize for it, and learn to move on, this requires also showing up as a mentee, articulating one’s needs, and learning to break the habits rooted in biases. Dr. Unaka warned against stereotypes and reminded us to look deeper and understand better all of our learners and their blind spots, as well as our own.
 

Key takeaways

  • The field of PHM must recognize the role that race plays in propagating inequalities.
  • Learning and mentorship environments have to be assessed for the safety of all learners and adjusted to correct (and autocorrect) as many biases as possible.
  • Institutions must assume responsibilities to establish a conscious, robust response to injustice and racism in a timely and specific manner.
  • Further research efforts must be made to address racism, rather than race.
  • The PHM community must show up to create a new, healthy, and deliberate bidirectional framework to endorse and support diversity.

Dr. Giordano is assistant professor of pediatrics at Columbia University and a pediatric hospitalist at NewYork–Presbyterian Morgan Stanley Children’s Hospital, both in New York, with an interest in surgical comanagement. She serves on the Society of Hospital Medicine’s Pediatric Special Interest Group Executive Committee and is the chair of the Education Subcommittee. She is also an advisory board member for the New York/Westchester SHM Chapter.

 

Presenters

Michael Bryant, MD – Children’s Hospital of Los Angeles

Kimberly Manning, MD – Emory University, Atlanta

Kimberly Reynolds, MD – University of Miami

Samir Shah, MD, MSCE, MHM – Cincinnati Children’s Hospital

Ndidi Unaka, MD, MEd – Cincinnati Children’s Hospital

Moderator

Erin Shaughnessy, MD – Phoenix Children’s Hospital

Session summary

This session was devoted to a discussion about how pediatric hospital medicine (PHM) as a field can address racism in medicine. The structural inequity rooted in poverty, housing problems, and differential education represents the essential social determinant of health. No longer can pediatric hospitalists neglect or be in denial of the crucial role that race plays in propagating further inequalities in our society and at our workplace. Historically Black people were exploited in research and still are disproportionately affected when it comes to infant prematurity and mortality, asthma, pain treatments, and so on. The pediatric hospitalist must explore and understand the reasons behind nonadherence and noncompliance among Black patients and always seek to understand before criticizing.

Dr. Mirna Giordano

Within learning environments, we must improve how to “autocorrect” and proactively work on our own biases. Dr. Bryant pointed out that each institution has the responsibility to build on the civil rights movement and seize the moment to create a robust response to the inequities manifested during the COVID-19 epidemic, as well as the events following the deaths of George Floyd, Breonna Taylor, Ahmoud Arbery, and many others. Dr. Shah called on the PHM community to take on that obligation by “stepping into the tension,” as Mark Shapiro, MD, has suggested in a conversation/podcast with Dr. Unaka.

As pediatric hospitalists, we will have to show up both individually and as constituents of institutions to address racism by specific projects looking at all data relevant for racism rather than race in quality and safety – thereby amplifying the voices of our Black patients and families, remarked Dr. Unaka. There was a brief reflection on the use of the word “allies” by Dr. Manning and Dr. Reynolds to remind the more than 200 session participants that a bidirectional framework of this process is crucial and that there is a clear need for a partnership to a common goal that should start by “a laydown of privilege of those who have it” to establish equal playing fields once and for all.

Dr. Bryant encouraged a deliberate and early thoughtful process to identify those with opportunities and help young Black people explore journeys in medicine and increase diversity among PHM faculty. Dr. Manning reminded the audience of the power that relationships have and hold in our lives, and not only those of mentors and mentees, but also relationships among all of us as humans. As with those simple situations in which we mess up and have to be able to admit it, apologize for it, and learn to move on, this requires also showing up as a mentee, articulating one’s needs, and learning to break the habits rooted in biases. Dr. Unaka warned against stereotypes and reminded us to look deeper and understand better all of our learners and their blind spots, as well as our own.
 

Key takeaways

  • The field of PHM must recognize the role that race plays in propagating inequalities.
  • Learning and mentorship environments have to be assessed for the safety of all learners and adjusted to correct (and autocorrect) as many biases as possible.
  • Institutions must assume responsibilities to establish a conscious, robust response to injustice and racism in a timely and specific manner.
  • Further research efforts must be made to address racism, rather than race.
  • The PHM community must show up to create a new, healthy, and deliberate bidirectional framework to endorse and support diversity.

Dr. Giordano is assistant professor of pediatrics at Columbia University and a pediatric hospitalist at NewYork–Presbyterian Morgan Stanley Children’s Hospital, both in New York, with an interest in surgical comanagement. She serves on the Society of Hospital Medicine’s Pediatric Special Interest Group Executive Committee and is the chair of the Education Subcommittee. She is also an advisory board member for the New York/Westchester SHM Chapter.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article

Colorism can lead to intrafamily conflict

Article Type
Changed
Thu, 10/29/2020 - 14:00

The color hue of a person’s skin is the most obvious criteria for society to judge a person and has always been deeply rooted in racism. Discrimination based on skin color is called colorism and is usually meted out by members of the same race and in the same family. The general belief is that someone with a lighter complexion is more beautiful, intelligent, or valuable than someone with a darker complexion. The term colorism can be widely applied in our assessment of conflict within families and society. The following case example gives guidance for psychiatrists faced with a family where colorism fuels family conflict.

Dr. Alison Heru
Dr. Alison M. Heru

Meeting the family

The Jaspers, a Black family, arrive at the psychiatrist’s office. They come in and look around before they choose their seats. Dr. Sally watches who sits next to whom and how they organize themselves in the office. After brief introductions, Mr. Jaspers begins, explaining why they are there.

“We are always fighting. We need this to stop. She, my wife, contradicts me all the time. Our kids are getting frustrated, and Bruce is acting out in school. He got in a fight again last week.”

Everyone looks at Bruce. He is darker skinned than the other siblings and carries all the African features in a family that favors the lighter end of the color spectrum. He sits next to his mother who leans into him. Mrs. Jaspers speaks next.

“Bruce gets picked on in school.”

Mr. Jaspers responds, “Well, if you didn’t run in there all the time and take him out, maybe he would learn how to deal with it better!”

“But they are mistreating him,” Mrs. Jaspers says.

The other children look away and play with their phones. Dr. Sally wonders whether this is a pattern: The parents fighting about how to deal with Bruce and his difficulties in the world – and the other siblings getting ignored and not included.

Dr. Sally asks Mrs. Jaspers for more details. She tells a narrative that is a strong thread in this family’s story.

“As you can see, Bruce is darker than the rest of our children. When we see the rest of our family, they all comment on what good skin and light coloring and good hair the other children have. Bruce just sits there. He is always being left out. He doesn’t speak up for himself. Maybe they think he can’t hear them, but I know he does and it affects him. They say the others are more intelligent, but I don’t think that is true. Bruce just gets picked on in school and he doesn’t feel like he matters. He doesn’t say anything, so maybe people think he doesn’t care, but I know he does.”

Dr. Sally turns to Bruce, who is still sitting silently next to his mother, his head down.

“Bruce, what do you have to say?”

Bruce shrugs his shoulders. His siblings still do not want to be drawn in and are otherwise occupied.

At this point, Dr. Sally might be thinking that she could see Bruce alone to assess his depression/self-esteem and maybe find ways to try to build him up. She does not want this to be an opportunity wasted. The goal is to work with the family to get Bruce where he needs to be faster and help the whole family.

Dr. Sally presses on. “Mr. Jaspers, what is your opinion?”

“She babies him. She treats him differently from the other kids. She is driving a wedge between him and his siblings. We fight about it all the time. She is driving a wedge between us, too.”

Mrs. Jaspers jumps in: “But you don’t know what it is like! When I was the only Black person in math class, I got picked on all the time! It made me self-conscious, and I couldn’t do my work. “

The other siblings look up briefly then back down at their devices. Dr. Sally asks them as a group:

“Can I ask you a question as a family? Can I ask the children a question?” They look up again. “Is this what goes on at home?” They all nod but offer no details.

Dr. Sally asks the oldest: “How does this affect your relationship with Bruce?”

They all look back and forth at each other. There is another long silence.

“See!” says Mr. Jaspers! “You can't protect him forever, and you are just ostracizing him from the rest of us! “

“But, but, he, he needs to learn different things. He is different. He faces different struggles. The police will stop him more. I am afraid for him.” Mrs. Jaspers starts to cry.

“You can’t protect him forever,” says her husband, gently reaching over to her.

Bruce has psychologically disappeared from the room, hiding behind his mother, who is now the largest and neediest presence in the room. Mr. Jaspers looks at Dr. Sally helplessly.

Dr. Sally asks the important question to the whole family.

“How do you all think this should work? If you don’t think Mrs. Jaspers is right, what do you think should be the way forward?”

This question is the turning point and indicates that Dr. Sally sees that the solution lies in how the family wants to manage things.

“I believe that your whole family has the answers, that you all have thought through this situation much more deeply and for much longer than I have. I am just hearing about it, and I am White and don’t have this experience. I have faith in your family, that with an opportunity to openly discuss this issue, that this knot can be unraveled. It does not mean that there are not more knots to unravel. For today, how to help you all help Bruce, is the work."

Dr. Sally talks to everyone but finishes up by looking at Mr. Jaspers, who has indicated that Bruce is part of the family and should not be treated differently from the other children.

Sean, the oldest sibling, now pipes up: “Bruce gets everything he wants. Mum spoils him; she always takes his side if there are arguments. Bruce knows this, and he steals our stuff because he knows he will get away with it.”

Bruce is quiet and leans in more to his mother. Dr. Sally motions to the mother not to speak.

“Is this true, Bruce?” Silence speaks that the answer is yes. The disparities in the family are aired for a while longer.

“Mrs. Jaspers, it is now your turn to respond.”

“Bruce is darker and faces more challenges than the others; he needs more protection and to know that he is loved.”

“Your family seems to think otherwise. They seem to think that your protection, while admirable, needs to be tempered to allow him to grow into a man who can stand on his own feet.”

Dr. Sally guides the family as a whole to a place where they can agree on the problem. The problem is now framed as a mother who cares too much and is too protective of Bruce but now her love and care need to be tempered. As a mother, she feels that it is her duty to protect her most vulnerable son. The family knows that Bruce will face more social scrutiny than the others, that he will have more internal struggles with self-worth than the others. How can the family help?

This conceptualization causes the family to look searchingly at one another. It is nothing they haven’t thought about privately, but this is the first time they are together thinking about it.

Dr. Sally says that she can help by providing time and space for them to wok through this together. They all agree to come back the following week with some thoughts about moving forward.
 

Offering perspective on colorism

In her book “Facing the Black Shadow,” couples and family therapist Marlene F. Watson, PhD, discusses colorism.

“African Americans still have a tough time talking about slavery – the origin of colorism. Seriously, what can we really expect to change without acknowledging and challenging the psychological residuals of slavery in our families and communities? What doesn’t get resolved in one generation is passed on to the next so our issues from slavery go from one generation to the next.”

Dr. Watson continues: “Confronting the secret about skin color in our families and communities is necessary for all Black girls to feel lovable, worthy, and deserving of care and for all Black boys to feel their value lies within them, not a dark, light, bright, near-white or White woman. African Americans need to get that preferring light over dark or dark over light is problematic for all of us. Skin color preferences in the African American community follow society’s racial hierarchy. African Americans as a group are at the bottom in the larger society and dark-skinned African Americans are at the bottom in the Black community.”

Dr. Watson suggests a way that we can help our patients. She encourages families to draw a family tree that tracks the family’s beliefs and patterns about skin color. Her advice is to ask each family member, from oldest to youngest, to identify the spoken and unspoken skin color beliefs he or she experiences in the family. Ask about skin color beliefs from outside that affect family members, and what each person thinks the family could do to stop promoting the “less than/better than” mentality that is often present with skin color assignment.



Thank you to Lynette Ramsingh Barros, who collaborated on creating the case.
 

Dr. Heru is professor of psychiatry at the University of Colorado Denver, Aurora. She is editor of “Working With Families in Medical Settings: A Multidisciplinary Guide for Psychiatrists and Other Health Professionals” (New York: Routledge, 2013). She has no conflicts of interest.

Publications
Topics
Sections

The color hue of a person’s skin is the most obvious criteria for society to judge a person and has always been deeply rooted in racism. Discrimination based on skin color is called colorism and is usually meted out by members of the same race and in the same family. The general belief is that someone with a lighter complexion is more beautiful, intelligent, or valuable than someone with a darker complexion. The term colorism can be widely applied in our assessment of conflict within families and society. The following case example gives guidance for psychiatrists faced with a family where colorism fuels family conflict.

Dr. Alison Heru
Dr. Alison M. Heru

Meeting the family

The Jaspers, a Black family, arrive at the psychiatrist’s office. They come in and look around before they choose their seats. Dr. Sally watches who sits next to whom and how they organize themselves in the office. After brief introductions, Mr. Jaspers begins, explaining why they are there.

“We are always fighting. We need this to stop. She, my wife, contradicts me all the time. Our kids are getting frustrated, and Bruce is acting out in school. He got in a fight again last week.”

Everyone looks at Bruce. He is darker skinned than the other siblings and carries all the African features in a family that favors the lighter end of the color spectrum. He sits next to his mother who leans into him. Mrs. Jaspers speaks next.

“Bruce gets picked on in school.”

Mr. Jaspers responds, “Well, if you didn’t run in there all the time and take him out, maybe he would learn how to deal with it better!”

“But they are mistreating him,” Mrs. Jaspers says.

The other children look away and play with their phones. Dr. Sally wonders whether this is a pattern: The parents fighting about how to deal with Bruce and his difficulties in the world – and the other siblings getting ignored and not included.

Dr. Sally asks Mrs. Jaspers for more details. She tells a narrative that is a strong thread in this family’s story.

“As you can see, Bruce is darker than the rest of our children. When we see the rest of our family, they all comment on what good skin and light coloring and good hair the other children have. Bruce just sits there. He is always being left out. He doesn’t speak up for himself. Maybe they think he can’t hear them, but I know he does and it affects him. They say the others are more intelligent, but I don’t think that is true. Bruce just gets picked on in school and he doesn’t feel like he matters. He doesn’t say anything, so maybe people think he doesn’t care, but I know he does.”

Dr. Sally turns to Bruce, who is still sitting silently next to his mother, his head down.

“Bruce, what do you have to say?”

Bruce shrugs his shoulders. His siblings still do not want to be drawn in and are otherwise occupied.

At this point, Dr. Sally might be thinking that she could see Bruce alone to assess his depression/self-esteem and maybe find ways to try to build him up. She does not want this to be an opportunity wasted. The goal is to work with the family to get Bruce where he needs to be faster and help the whole family.

Dr. Sally presses on. “Mr. Jaspers, what is your opinion?”

“She babies him. She treats him differently from the other kids. She is driving a wedge between him and his siblings. We fight about it all the time. She is driving a wedge between us, too.”

Mrs. Jaspers jumps in: “But you don’t know what it is like! When I was the only Black person in math class, I got picked on all the time! It made me self-conscious, and I couldn’t do my work. “

The other siblings look up briefly then back down at their devices. Dr. Sally asks them as a group:

“Can I ask you a question as a family? Can I ask the children a question?” They look up again. “Is this what goes on at home?” They all nod but offer no details.

Dr. Sally asks the oldest: “How does this affect your relationship with Bruce?”

They all look back and forth at each other. There is another long silence.

“See!” says Mr. Jaspers! “You can't protect him forever, and you are just ostracizing him from the rest of us! “

“But, but, he, he needs to learn different things. He is different. He faces different struggles. The police will stop him more. I am afraid for him.” Mrs. Jaspers starts to cry.

“You can’t protect him forever,” says her husband, gently reaching over to her.

Bruce has psychologically disappeared from the room, hiding behind his mother, who is now the largest and neediest presence in the room. Mr. Jaspers looks at Dr. Sally helplessly.

Dr. Sally asks the important question to the whole family.

“How do you all think this should work? If you don’t think Mrs. Jaspers is right, what do you think should be the way forward?”

This question is the turning point and indicates that Dr. Sally sees that the solution lies in how the family wants to manage things.

“I believe that your whole family has the answers, that you all have thought through this situation much more deeply and for much longer than I have. I am just hearing about it, and I am White and don’t have this experience. I have faith in your family, that with an opportunity to openly discuss this issue, that this knot can be unraveled. It does not mean that there are not more knots to unravel. For today, how to help you all help Bruce, is the work."

Dr. Sally talks to everyone but finishes up by looking at Mr. Jaspers, who has indicated that Bruce is part of the family and should not be treated differently from the other children.

Sean, the oldest sibling, now pipes up: “Bruce gets everything he wants. Mum spoils him; she always takes his side if there are arguments. Bruce knows this, and he steals our stuff because he knows he will get away with it.”

Bruce is quiet and leans in more to his mother. Dr. Sally motions to the mother not to speak.

“Is this true, Bruce?” Silence speaks that the answer is yes. The disparities in the family are aired for a while longer.

“Mrs. Jaspers, it is now your turn to respond.”

“Bruce is darker and faces more challenges than the others; he needs more protection and to know that he is loved.”

“Your family seems to think otherwise. They seem to think that your protection, while admirable, needs to be tempered to allow him to grow into a man who can stand on his own feet.”

Dr. Sally guides the family as a whole to a place where they can agree on the problem. The problem is now framed as a mother who cares too much and is too protective of Bruce but now her love and care need to be tempered. As a mother, she feels that it is her duty to protect her most vulnerable son. The family knows that Bruce will face more social scrutiny than the others, that he will have more internal struggles with self-worth than the others. How can the family help?

This conceptualization causes the family to look searchingly at one another. It is nothing they haven’t thought about privately, but this is the first time they are together thinking about it.

Dr. Sally says that she can help by providing time and space for them to wok through this together. They all agree to come back the following week with some thoughts about moving forward.
 

Offering perspective on colorism

In her book “Facing the Black Shadow,” couples and family therapist Marlene F. Watson, PhD, discusses colorism.

“African Americans still have a tough time talking about slavery – the origin of colorism. Seriously, what can we really expect to change without acknowledging and challenging the psychological residuals of slavery in our families and communities? What doesn’t get resolved in one generation is passed on to the next so our issues from slavery go from one generation to the next.”

Dr. Watson continues: “Confronting the secret about skin color in our families and communities is necessary for all Black girls to feel lovable, worthy, and deserving of care and for all Black boys to feel their value lies within them, not a dark, light, bright, near-white or White woman. African Americans need to get that preferring light over dark or dark over light is problematic for all of us. Skin color preferences in the African American community follow society’s racial hierarchy. African Americans as a group are at the bottom in the larger society and dark-skinned African Americans are at the bottom in the Black community.”

Dr. Watson suggests a way that we can help our patients. She encourages families to draw a family tree that tracks the family’s beliefs and patterns about skin color. Her advice is to ask each family member, from oldest to youngest, to identify the spoken and unspoken skin color beliefs he or she experiences in the family. Ask about skin color beliefs from outside that affect family members, and what each person thinks the family could do to stop promoting the “less than/better than” mentality that is often present with skin color assignment.



Thank you to Lynette Ramsingh Barros, who collaborated on creating the case.
 

Dr. Heru is professor of psychiatry at the University of Colorado Denver, Aurora. She is editor of “Working With Families in Medical Settings: A Multidisciplinary Guide for Psychiatrists and Other Health Professionals” (New York: Routledge, 2013). She has no conflicts of interest.

The color hue of a person’s skin is the most obvious criteria for society to judge a person and has always been deeply rooted in racism. Discrimination based on skin color is called colorism and is usually meted out by members of the same race and in the same family. The general belief is that someone with a lighter complexion is more beautiful, intelligent, or valuable than someone with a darker complexion. The term colorism can be widely applied in our assessment of conflict within families and society. The following case example gives guidance for psychiatrists faced with a family where colorism fuels family conflict.

Dr. Alison Heru
Dr. Alison M. Heru

Meeting the family

The Jaspers, a Black family, arrive at the psychiatrist’s office. They come in and look around before they choose their seats. Dr. Sally watches who sits next to whom and how they organize themselves in the office. After brief introductions, Mr. Jaspers begins, explaining why they are there.

“We are always fighting. We need this to stop. She, my wife, contradicts me all the time. Our kids are getting frustrated, and Bruce is acting out in school. He got in a fight again last week.”

Everyone looks at Bruce. He is darker skinned than the other siblings and carries all the African features in a family that favors the lighter end of the color spectrum. He sits next to his mother who leans into him. Mrs. Jaspers speaks next.

“Bruce gets picked on in school.”

Mr. Jaspers responds, “Well, if you didn’t run in there all the time and take him out, maybe he would learn how to deal with it better!”

“But they are mistreating him,” Mrs. Jaspers says.

The other children look away and play with their phones. Dr. Sally wonders whether this is a pattern: The parents fighting about how to deal with Bruce and his difficulties in the world – and the other siblings getting ignored and not included.

Dr. Sally asks Mrs. Jaspers for more details. She tells a narrative that is a strong thread in this family’s story.

“As you can see, Bruce is darker than the rest of our children. When we see the rest of our family, they all comment on what good skin and light coloring and good hair the other children have. Bruce just sits there. He is always being left out. He doesn’t speak up for himself. Maybe they think he can’t hear them, but I know he does and it affects him. They say the others are more intelligent, but I don’t think that is true. Bruce just gets picked on in school and he doesn’t feel like he matters. He doesn’t say anything, so maybe people think he doesn’t care, but I know he does.”

Dr. Sally turns to Bruce, who is still sitting silently next to his mother, his head down.

“Bruce, what do you have to say?”

Bruce shrugs his shoulders. His siblings still do not want to be drawn in and are otherwise occupied.

At this point, Dr. Sally might be thinking that she could see Bruce alone to assess his depression/self-esteem and maybe find ways to try to build him up. She does not want this to be an opportunity wasted. The goal is to work with the family to get Bruce where he needs to be faster and help the whole family.

Dr. Sally presses on. “Mr. Jaspers, what is your opinion?”

“She babies him. She treats him differently from the other kids. She is driving a wedge between him and his siblings. We fight about it all the time. She is driving a wedge between us, too.”

Mrs. Jaspers jumps in: “But you don’t know what it is like! When I was the only Black person in math class, I got picked on all the time! It made me self-conscious, and I couldn’t do my work. “

The other siblings look up briefly then back down at their devices. Dr. Sally asks them as a group:

“Can I ask you a question as a family? Can I ask the children a question?” They look up again. “Is this what goes on at home?” They all nod but offer no details.

Dr. Sally asks the oldest: “How does this affect your relationship with Bruce?”

They all look back and forth at each other. There is another long silence.

“See!” says Mr. Jaspers! “You can't protect him forever, and you are just ostracizing him from the rest of us! “

“But, but, he, he needs to learn different things. He is different. He faces different struggles. The police will stop him more. I am afraid for him.” Mrs. Jaspers starts to cry.

“You can’t protect him forever,” says her husband, gently reaching over to her.

Bruce has psychologically disappeared from the room, hiding behind his mother, who is now the largest and neediest presence in the room. Mr. Jaspers looks at Dr. Sally helplessly.

Dr. Sally asks the important question to the whole family.

“How do you all think this should work? If you don’t think Mrs. Jaspers is right, what do you think should be the way forward?”

This question is the turning point and indicates that Dr. Sally sees that the solution lies in how the family wants to manage things.

“I believe that your whole family has the answers, that you all have thought through this situation much more deeply and for much longer than I have. I am just hearing about it, and I am White and don’t have this experience. I have faith in your family, that with an opportunity to openly discuss this issue, that this knot can be unraveled. It does not mean that there are not more knots to unravel. For today, how to help you all help Bruce, is the work."

Dr. Sally talks to everyone but finishes up by looking at Mr. Jaspers, who has indicated that Bruce is part of the family and should not be treated differently from the other children.

Sean, the oldest sibling, now pipes up: “Bruce gets everything he wants. Mum spoils him; she always takes his side if there are arguments. Bruce knows this, and he steals our stuff because he knows he will get away with it.”

Bruce is quiet and leans in more to his mother. Dr. Sally motions to the mother not to speak.

“Is this true, Bruce?” Silence speaks that the answer is yes. The disparities in the family are aired for a while longer.

“Mrs. Jaspers, it is now your turn to respond.”

“Bruce is darker and faces more challenges than the others; he needs more protection and to know that he is loved.”

“Your family seems to think otherwise. They seem to think that your protection, while admirable, needs to be tempered to allow him to grow into a man who can stand on his own feet.”

Dr. Sally guides the family as a whole to a place where they can agree on the problem. The problem is now framed as a mother who cares too much and is too protective of Bruce but now her love and care need to be tempered. As a mother, she feels that it is her duty to protect her most vulnerable son. The family knows that Bruce will face more social scrutiny than the others, that he will have more internal struggles with self-worth than the others. How can the family help?

This conceptualization causes the family to look searchingly at one another. It is nothing they haven’t thought about privately, but this is the first time they are together thinking about it.

Dr. Sally says that she can help by providing time and space for them to wok through this together. They all agree to come back the following week with some thoughts about moving forward.
 

Offering perspective on colorism

In her book “Facing the Black Shadow,” couples and family therapist Marlene F. Watson, PhD, discusses colorism.

“African Americans still have a tough time talking about slavery – the origin of colorism. Seriously, what can we really expect to change without acknowledging and challenging the psychological residuals of slavery in our families and communities? What doesn’t get resolved in one generation is passed on to the next so our issues from slavery go from one generation to the next.”

Dr. Watson continues: “Confronting the secret about skin color in our families and communities is necessary for all Black girls to feel lovable, worthy, and deserving of care and for all Black boys to feel their value lies within them, not a dark, light, bright, near-white or White woman. African Americans need to get that preferring light over dark or dark over light is problematic for all of us. Skin color preferences in the African American community follow society’s racial hierarchy. African Americans as a group are at the bottom in the larger society and dark-skinned African Americans are at the bottom in the Black community.”

Dr. Watson suggests a way that we can help our patients. She encourages families to draw a family tree that tracks the family’s beliefs and patterns about skin color. Her advice is to ask each family member, from oldest to youngest, to identify the spoken and unspoken skin color beliefs he or she experiences in the family. Ask about skin color beliefs from outside that affect family members, and what each person thinks the family could do to stop promoting the “less than/better than” mentality that is often present with skin color assignment.



Thank you to Lynette Ramsingh Barros, who collaborated on creating the case.
 

Dr. Heru is professor of psychiatry at the University of Colorado Denver, Aurora. She is editor of “Working With Families in Medical Settings: A Multidisciplinary Guide for Psychiatrists and Other Health Professionals” (New York: Routledge, 2013). She has no conflicts of interest.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article

Strengthening faith during coronavirus: An Islamic perspective

Article Type
Changed
Mon, 01/11/2021 - 09:39
Display Headline
Strengthening faith during coronavirus: An Islamic perspective

"Ramadan will be depressing this year,” a patient told me as I entered the room for an evaluation. This is one of many similar reactions my patients expressed in March, when mosques began to close and social distancing parameters were put in place to limit the spread of coronavirus disease 2019 (COVID-19). Muslims began to adjust to new social norms, such as replacing warm hugs with waving hands from 6 feet away. They were suddenly advised to avoid century-long cultural practices, such as spending time with extended family, visiting the sick and the elderly, and meeting for Jummah (Friday) prayer at mosque. With increasing anxiety and uncertainty in the air, I began thinking about how the pandemic would psychologically affect Islamic spirituality, especially during Ramadan (the Islamic month of fasting) this year.

As a Muslim psychiatry resident working on an inpatient psychiatric unit and in a psychiatry consultation service during the COVID-19 pandemic, I often explore spirituality and faith with my patients as a way of providing supportive therapy for anxiety. Many of my Christian patients endorsed anxiety about how Easter would be “terrible” this year because they could not attend church. Upon hearing this, I realized that I could not picture a Ramadan during which I was not permitted to go to mosque. How was I supposed to provide supportive therapy for my patients when I also felt so uncertain? These concerns led me to take a step back and remind myself of what I frequently tell my patients when they feel hopeless: “With every difficulty, there comes an opportunity to gain a new perspective.”

A time for spirituality

When Ramadan began in April, many people who are Muslim and were working from home told me that it felt strange to have so much time during the day to pray, reflect, and read the Quran. Others mentioned that they enjoyed the peace of Iftar (breaking fast) at home, because they could avoid the hustle and bustle of this at mosque. Halfway through Ramadan, a Muslim patient I was treating reported that her “coronavirus anxiety” had improved as she began focusing her energy on Allah, rather than spending hours watching the news and obsessing over death tolls.

Due to the pandemic, many more opportunities for donating to those in need arose, which led my religious community to perform Zakat (providing charity) and send supplies to food banks in our area. Because of social distancing, Muslim families were able to spend more time preparing meals, learning together, and supporting each other. Although mosques were closed due to the pandemic, it seemed as though each home became its own gathering place for spirituality, gratitude, and self-reflection. By the end of Ramadan, the values of self-discipline, empathy, and patience became self-evident.

Increased attention to mental health among Muslims

Psychologically, I believe resilience has grown stronger among Muslims worldwide during this pandemic. Along with adopting a positive mindset, Muslims have committed to creating their own routines to combat anxiety during this stressful time. The Salat (praying 5 times a day) and Taharat (cleanliness) that Islam emphasizes have been helpful in creating structure to offset the uncertainty and fear that is associated with COVID-19.

The discussion of mental illness, which previously has been regarded as a culturally stigmatized topic, has been gaining significant recognition within Islamic communities. Depression, anxiety, and self-care are now emphasized during virtual sermons, and contact information for mental health hotlines and professionals are being rapidly disseminated. There is now a greater sense of encouragement for people of Islamic faith to seek psychiatric help when needed.

Although COVID-19 has limited some social and physical religious practices, this pandemic has helped to strengthen faith and spirituality not only among Muslims, but also people of other faiths. During periods of stress, change, and uncertainty, it is important to remember that “With every difficulty, there comes an opportunity to gain a new perspective.” Although mosques and churches continue to stay closed and anxiety persists, I can now confidently reassure my patients that through this experience we are becoming resilient and learning to value patience, gratitude, and empathy more than ever.

Article PDF
Author and Disclosure Information

Dr. Saherwala is a PGY-3 Psychiatry Resident, Wright State University, Dayton, Ohio.

Disclosure
The author reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Issue
Current Psychiatry - 19(9)
Publications
Topics
Page Number
e1-e2
Sections
Author and Disclosure Information

Dr. Saherwala is a PGY-3 Psychiatry Resident, Wright State University, Dayton, Ohio.

Disclosure
The author reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Author and Disclosure Information

Dr. Saherwala is a PGY-3 Psychiatry Resident, Wright State University, Dayton, Ohio.

Disclosure
The author reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Article PDF
Article PDF

"Ramadan will be depressing this year,” a patient told me as I entered the room for an evaluation. This is one of many similar reactions my patients expressed in March, when mosques began to close and social distancing parameters were put in place to limit the spread of coronavirus disease 2019 (COVID-19). Muslims began to adjust to new social norms, such as replacing warm hugs with waving hands from 6 feet away. They were suddenly advised to avoid century-long cultural practices, such as spending time with extended family, visiting the sick and the elderly, and meeting for Jummah (Friday) prayer at mosque. With increasing anxiety and uncertainty in the air, I began thinking about how the pandemic would psychologically affect Islamic spirituality, especially during Ramadan (the Islamic month of fasting) this year.

As a Muslim psychiatry resident working on an inpatient psychiatric unit and in a psychiatry consultation service during the COVID-19 pandemic, I often explore spirituality and faith with my patients as a way of providing supportive therapy for anxiety. Many of my Christian patients endorsed anxiety about how Easter would be “terrible” this year because they could not attend church. Upon hearing this, I realized that I could not picture a Ramadan during which I was not permitted to go to mosque. How was I supposed to provide supportive therapy for my patients when I also felt so uncertain? These concerns led me to take a step back and remind myself of what I frequently tell my patients when they feel hopeless: “With every difficulty, there comes an opportunity to gain a new perspective.”

A time for spirituality

When Ramadan began in April, many people who are Muslim and were working from home told me that it felt strange to have so much time during the day to pray, reflect, and read the Quran. Others mentioned that they enjoyed the peace of Iftar (breaking fast) at home, because they could avoid the hustle and bustle of this at mosque. Halfway through Ramadan, a Muslim patient I was treating reported that her “coronavirus anxiety” had improved as she began focusing her energy on Allah, rather than spending hours watching the news and obsessing over death tolls.

Due to the pandemic, many more opportunities for donating to those in need arose, which led my religious community to perform Zakat (providing charity) and send supplies to food banks in our area. Because of social distancing, Muslim families were able to spend more time preparing meals, learning together, and supporting each other. Although mosques were closed due to the pandemic, it seemed as though each home became its own gathering place for spirituality, gratitude, and self-reflection. By the end of Ramadan, the values of self-discipline, empathy, and patience became self-evident.

Increased attention to mental health among Muslims

Psychologically, I believe resilience has grown stronger among Muslims worldwide during this pandemic. Along with adopting a positive mindset, Muslims have committed to creating their own routines to combat anxiety during this stressful time. The Salat (praying 5 times a day) and Taharat (cleanliness) that Islam emphasizes have been helpful in creating structure to offset the uncertainty and fear that is associated with COVID-19.

The discussion of mental illness, which previously has been regarded as a culturally stigmatized topic, has been gaining significant recognition within Islamic communities. Depression, anxiety, and self-care are now emphasized during virtual sermons, and contact information for mental health hotlines and professionals are being rapidly disseminated. There is now a greater sense of encouragement for people of Islamic faith to seek psychiatric help when needed.

Although COVID-19 has limited some social and physical religious practices, this pandemic has helped to strengthen faith and spirituality not only among Muslims, but also people of other faiths. During periods of stress, change, and uncertainty, it is important to remember that “With every difficulty, there comes an opportunity to gain a new perspective.” Although mosques and churches continue to stay closed and anxiety persists, I can now confidently reassure my patients that through this experience we are becoming resilient and learning to value patience, gratitude, and empathy more than ever.

"Ramadan will be depressing this year,” a patient told me as I entered the room for an evaluation. This is one of many similar reactions my patients expressed in March, when mosques began to close and social distancing parameters were put in place to limit the spread of coronavirus disease 2019 (COVID-19). Muslims began to adjust to new social norms, such as replacing warm hugs with waving hands from 6 feet away. They were suddenly advised to avoid century-long cultural practices, such as spending time with extended family, visiting the sick and the elderly, and meeting for Jummah (Friday) prayer at mosque. With increasing anxiety and uncertainty in the air, I began thinking about how the pandemic would psychologically affect Islamic spirituality, especially during Ramadan (the Islamic month of fasting) this year.

As a Muslim psychiatry resident working on an inpatient psychiatric unit and in a psychiatry consultation service during the COVID-19 pandemic, I often explore spirituality and faith with my patients as a way of providing supportive therapy for anxiety. Many of my Christian patients endorsed anxiety about how Easter would be “terrible” this year because they could not attend church. Upon hearing this, I realized that I could not picture a Ramadan during which I was not permitted to go to mosque. How was I supposed to provide supportive therapy for my patients when I also felt so uncertain? These concerns led me to take a step back and remind myself of what I frequently tell my patients when they feel hopeless: “With every difficulty, there comes an opportunity to gain a new perspective.”

A time for spirituality

When Ramadan began in April, many people who are Muslim and were working from home told me that it felt strange to have so much time during the day to pray, reflect, and read the Quran. Others mentioned that they enjoyed the peace of Iftar (breaking fast) at home, because they could avoid the hustle and bustle of this at mosque. Halfway through Ramadan, a Muslim patient I was treating reported that her “coronavirus anxiety” had improved as she began focusing her energy on Allah, rather than spending hours watching the news and obsessing over death tolls.

Due to the pandemic, many more opportunities for donating to those in need arose, which led my religious community to perform Zakat (providing charity) and send supplies to food banks in our area. Because of social distancing, Muslim families were able to spend more time preparing meals, learning together, and supporting each other. Although mosques were closed due to the pandemic, it seemed as though each home became its own gathering place for spirituality, gratitude, and self-reflection. By the end of Ramadan, the values of self-discipline, empathy, and patience became self-evident.

Increased attention to mental health among Muslims

Psychologically, I believe resilience has grown stronger among Muslims worldwide during this pandemic. Along with adopting a positive mindset, Muslims have committed to creating their own routines to combat anxiety during this stressful time. The Salat (praying 5 times a day) and Taharat (cleanliness) that Islam emphasizes have been helpful in creating structure to offset the uncertainty and fear that is associated with COVID-19.

The discussion of mental illness, which previously has been regarded as a culturally stigmatized topic, has been gaining significant recognition within Islamic communities. Depression, anxiety, and self-care are now emphasized during virtual sermons, and contact information for mental health hotlines and professionals are being rapidly disseminated. There is now a greater sense of encouragement for people of Islamic faith to seek psychiatric help when needed.

Although COVID-19 has limited some social and physical religious practices, this pandemic has helped to strengthen faith and spirituality not only among Muslims, but also people of other faiths. During periods of stress, change, and uncertainty, it is important to remember that “With every difficulty, there comes an opportunity to gain a new perspective.” Although mosques and churches continue to stay closed and anxiety persists, I can now confidently reassure my patients that through this experience we are becoming resilient and learning to value patience, gratitude, and empathy more than ever.

Issue
Current Psychiatry - 19(9)
Issue
Current Psychiatry - 19(9)
Page Number
e1-e2
Page Number
e1-e2
Publications
Publications
Topics
Article Type
Display Headline
Strengthening faith during coronavirus: An Islamic perspective
Display Headline
Strengthening faith during coronavirus: An Islamic perspective
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media